Every forecast, sealed until the trial reads out.
26,682 forecasts sealed since Sep 29, 2026. New trials are sealed every night, and none is ever edited.
997 of 997 trials
| May 17, 2026 | A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaNCT06022861 · LY01015, Fluorouracil, Cisplatin | Shandong Boan Biotechnology Co., Ltd | Oncology | Phase 3 | 510 | SealedSep 29, 2026 |
| May 18, 2026 | Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07168902 · BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5% | Bausch & Lomb Incorporated | Ophthalmology | Phase 2 | 252 | SealedSep 29, 2026 |
| May 18, 2026 | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435 · sigvotatug vedotin, docetaxel | Seagen, a wholly owned subsidiary of Pfizer | Oncology | Phase 3 | 762 | SealedSep 29, 2026 |
| May 18, 2026 | Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μgNCT05569239 · OVX836 480µg, Saline Solution | Osivax | Infectious disease & vaccines | Phase 2 | 2,891 | SealedSep 29, 2026 |
| May 18, 2026 | Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection FractionNCT06017609 · JTT-861 Capsules, Placebo Capsules | Shionogi Inc. | Cardiovascular | Phase 2 | 314 | Not forecastNo arm registered as a control |
| May 19, 2026 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerNCT06497556 · Divarasib, Sotorasib, Adagrasib | Hoffmann-La Roche | Oncology | Phase 3 | 338 | SealedSep 29, 2026 |
| May 20, 2026 | A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Placebo, DT120 | Definium Therapeutics US, Inc. | Psychiatry | Phase 3 | 149 | SealedSep 29, 2026 |
| May 20, 2026 | Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).NCT07264517 · GRF312 5%, Placebo Comparator | Instituto Grifols, S.A. | Ophthalmology | Phase 2 | 103 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| May 20, 2026 | Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisNCT05327127 · K-877-ER, CSG452, Placebo | Kowa Research Institute, Inc. | Liver | Phase 2 | 228 | SealedSep 29, 2026 |
| May 22, 2026 | A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseaseNCT05280548 · Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828) | Sanofi | Rare genetic disease | Phase 3 | 104 | SealedSep 29, 2026 |
| May 22, 2026 | A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic MyopiaNCT06176352 · Faricimab, Ranibizumab, Sham Procedure | Hoffmann-La Roche | Ophthalmology | Phase 3 | 280 | SealedSep 29, 2026 |
| May 22, 2026 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931 · Selinexor, Matching Placebo for selinexor | Karyopharm Therapeutics Inc | Oncology | Phase 3 | 257 | SealedSep 29, 2026 |
| May 23, 2026 | Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLNCT06601504 · HMPL-760 planned dose 1, R-GemOx, HMPL-760 placebo planned dose 1 | Hutchmed | Oncology | Phase 2 | 61 | SealedSep 29, 2026 |
| May 25, 2026 | A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisNCT06878404 · Icotrokinra, Placebo, Active reference comparator | Janssen Research & Development, LLC | Immunology & inflammation | Phase 3 | 552 | SealedSep 29, 2026 |
| May 25, 2026 | A Study of ONO-1110 in Patients With Social Anxiety DisorderNCT06805565 · ONO-1110, Placebo | Ono Pharmaceutical Co., Ltd. | Psychiatry | Phase 2 | 115 | SealedSep 29, 2026 |
| May 25, 2026 | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersNCT06143046 · mRNA-1345, Placebo | ModernaTX, Inc. | Infectious disease & vaccines | Phase 2 | 360 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| May 26, 2026 | Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma SubjectsNCT07054034 · MG-ZG122 Humanized Monoclonal Antibody Injection, Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Respiratory | Phase 2 | 160 | SealedSep 29, 2026 |
| May 26, 2026 | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgeNCT06087640 · aQIV or aTIV, QIV or TIV | Seqirus | Infectious disease & vaccines | Phase 3 | 38,769 | Not forecastNo arm registered as a control |
| May 26, 2026 | A Study of Mosliciguat in PH-ILDNCT06635850 · Mosliciguat, Dry Powder Inhaler, Placebo | Pulmovant, Inc. | Cardiovascular | Phase 2 | 135 | SealedSep 29, 2026 |
| May 26, 2026 | A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)NCT06490445 · Medical Cannabis, Placebo | Syqe Medical | Diabetes & obesity | Phase 2 | 122 | SealedSep 29, 2026 |
| May 26, 2026 | Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AgonistNCT06851858 · AZD6234, Placebo to match | AstraZeneca | Diabetes & obesity | Phase 2 | 69 | SealedSep 29, 2026 |
| May 26, 2026 | Study to Assess the Efficacy of EMC-CAP-2025A on Age-Related Skin Parameters in Healthy IndividualsNCT07493850 · EMC-CAP-2025A, EMC-CAP-2025B | Circul'Egg | Other | Phase 2 | 60 | Not forecastNot a treatment or prevention trial |
| May 27, 2026 | Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With KeratoconusNCT06100939 · Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment | Epion Therapeutics | Ophthalmology | Phase 3 | 396 | SealedSep 29, 2026 |
| May 27, 2026 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationNCT03383458 · Nivolumab, Placebo | Bristol-Myers Squibb | Oncology | Phase 3 | 545 | SealedSep 29, 2026 |
| May 27, 2026 | Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERDNCT05556824 · MHS-1031, Placebo | Microbiome Health Sciences | Other | Phase 2 | 255 | SealedSep 29, 2026 |
| May 27, 2026 | A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)NCT07716618 · SAL0120 1mg, SAL0120 2mg, SAL0120 4mg | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Kidney | Phase 2 | 320 | SealedSep 29, 2026 |
| May 27, 2026 | A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)NCT05996471 · VH3810109, Cabotegravir, Standard of care (SOC) | ViiV Healthcare | Infectious disease & vaccines | Phase 2 | 185 | SealedSep 29, 2026 |
| May 27, 2026 | A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent PatientsNCT07036419 · Remimazolam Tosilate for injection, Propofol Injection | Jiangsu HengRui Medicine Co., Ltd. | Other | Phase 2/3 | 249 | SealedSep 29, 2026 |
| May 27, 2026 | Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes MellitusNCT07055516 · NT-0796, Placebo | NodThera Ltd. (a Rezera company) | Diabetes & obesity | Phase 2 | 176 | SealedSep 29, 2026 |
| May 28, 2026 | A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseNCT07128628 · Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane | Bausch & Lomb Incorporated | Ophthalmology | Phase 2 | 443 | SealedSep 29, 2026 |
| May 28, 2026 | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)NCT07155668 · VRDN-003, Autoinjector | Viridian Therapeutics, Inc. | Ophthalmology | Phase 3 | 87 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| May 28, 2026 | Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)NCT06513312 · Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Infectious disease & vaccines | Phase 2 | 268 | SealedSep 29, 2026 |
| May 28, 2026 | A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsNCT06047444 · Botulinum toxin type A, Botulinum toxin type A, Placebo | Ipsen | Neurology | Phase 3 | 759 | SealedSep 29, 2026 |
| May 28, 2026 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugNCT06641076 · Sonelokimab, Placebo | MoonLake Immunotherapeutics AG | Immunology & inflammation | Phase 3 | 960 | SealedSep 29, 2026 |
| May 28, 2026 | A Study to Learn More About How Well Oxymetazoline HCl 0.05% Nasal Gel Works and How Safe It Is in Healthy AdultsNCT07582328 · Oxymetazoline HCl 0.05% nasal gel, Placebo nasal gel | Bayer | Other | Phase 2 | 120 | SealedSep 29, 2026 |
| May 29, 2026 | Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)NCT06873516 · EVO756, EVO756, EVO756 | Evommune, Inc. | Immunology & inflammation | Phase 2 | 182 | SealedSep 29, 2026 |
| May 29, 2026 | A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 · Placebo, Enicepatide | Carmot Therapeutics, Inc. | Diabetes & obesity | Phase 2 | 447 | SealedSep 29, 2026 |
| May 29, 2026 | A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With MetforminNCT06589765 · HRS-7535 tablet, dapagliflozin tablet | Shandong Suncadia Medicine Co., Ltd. | Diabetes & obesity | Phase 3 | 810 | SealedSep 29, 2026 |
| May 30, 2026 | A Clinical Study of ONO-1110 in Patients With FibromyalgiaNCT06752590 · ONO-1110, Placebo | Ono Pharmaceutical Co., Ltd. | Other | Phase 2 | 175 | SealedSep 29, 2026 |
| May 31, 2026 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2NCT06346392 · AZD0901, AZD0901, Ramucirumab+ paclitaxel | AstraZeneca | Oncology | Phase 3 | 594 | SealedSep 29, 2026 |
| Jun 2026 | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or RecurrenceNCT06336291 · L19TNF, L19TNF, L19TNF | Philogen S.p.A. | Oncology | Phase 2 | 90 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 2026 | Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque PsoriasisNCT06640517 · Netakimab, Placebo, Adalimumab | Biocad | Immunology & inflammation | Phase 3 | 140 | SealedSep 29, 2026 |
| Jun 2026 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320 · RMC-6236, Gemcitabine, nab-paclitaxel | Revolution Medicines, Inc. | Oncology | Phase 3 | 500 | SealedSep 29, 2026 |
| Jun 2026 | Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette SyndromeNCT06315751 · Gemlapodect, Placebo | Noema Pharma AG | Other | Phase 2 | 164 | SealedSep 29, 2026 |
| Jun 2026 | A Study of Telitacicept for IgA Nephropathy (TELIGAN)NCT05799287 · Telitacicept, Placebo | RemeGen Co., Ltd. | Kidney | Phase 3 | 318 | SealedSep 29, 2026 |
| Jun 2026 | 9-ING-41 in Patients With Advanced CancersNCT03678883 · 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. | Actuate Therapeutics Inc. | Oncology | Phase 2 | 350 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 1, 2026 | Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaNCT06347133 · Plozasiran Injection, Placebo | Arrowhead Pharmaceuticals | Diabetes & obesity | Phase 3 | 1,456 | SealedSep 29, 2026 |
| Jun 1, 2026 | A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in AdultsNCT06047457 · Botulinum toxin type A, Botulinum toxin type A, Placebo | Ipsen | Neurology | Phase 3 | 751 | SealedSep 29, 2026 |
| Jun 1, 2026 | Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerNCT03682068 · Durvalumab, Tremelimumab, Cisplatin + Gemcitabine | AstraZeneca | Oncology | Phase 3 | 1,246 | SealedSep 29, 2026 |
| Jun 1, 2026 | Clinical Study to Assess the Efficacy of New Toothpaste Containing SnF as Compared to Colgate Cavity Protection Toothpaste on the Reduction of Enamel ErosionNCT07442136 · New Toothpaste Containing SnF, Fluoride Toothpaste | Colgate Palmolive | Other | Phase 3 | 80 | SealedSep 29, 2026 |
| Jun 1, 2026 | A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · survodutide, Placebo | Boehringer Ingelheim | Diabetes & obesity | Phase 3 | 5,530 | SealedSep 29, 2026 |
| Jun 2, 2026 | A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT06075667 · Tirzepatide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 160 | SealedSep 29, 2026 |
| Jun 2, 2026 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 · Cagrilintide, Semaglutide, Tirzepatide | Novo Nordisk A/S | Diabetes & obesity | Phase 3 | 1,023 | Not forecastNo arm registered as a control |
| Jun 3, 2026 | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationNCT06116890 · KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Ophthalmology | Phase 2 | 170 | Not forecastNo arm registered as a control |
| Jun 3, 2026 | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaNCT04712097 · Mosunetuzumab, Lenalidomide, Rituximab | Hoffmann-La Roche | Oncology | Phase 3 | 478 | Not forecastNo arm registered as a control |
| Jun 4, 2026 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaNCT07038876 · Placebo, ML-007C-MA BID, ML-007C-MA QD | MapLight Therapeutics | Psychiatry | Phase 2 | 307 | SealedSep 29, 2026 |
| Jun 5, 2026 | A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United StatesNCT07122193 · NT 201, NT 201 Placebo | Merz North America, Inc. | Other | Phase 3 | 300 | SealedSep 29, 2026 |
| Jun 5, 2026 | A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic ArthritisNCT06640257 · SHR-1314 injection, Placebo | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Immunology & inflammation | Phase 3 | 208 | SealedSep 29, 2026 |
| Jun 6, 2026 | Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard ToothbrushNCT07471477 · Colgate 360 SupraClean Manual Toothbrush brush with 0.76% Na MFP, (1000 ppm F), Colgate Adult Extra Clean soft-bristle toothbrush brush with 0.76% Na MFP, (1000 ppm F) | Colgate Palmolive | Other | Phase 3 | 56 | SealedSep 29, 2026 |
| Jun 7, 2026 | A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody TherapyNCT06945107 · Picankibart, Secukinumab, Placebo | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Immunology & inflammation | Phase 3 | 308 | SealedSep 29, 2026 |
| Jun 7, 2026 | A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis BNCT07135349 · BW-20507 with/without NUC, BW-20507 with/without NUC, Peg-IFNa | Shanghai Argo Biopharmaceutical Co., Ltd. | Infectious disease & vaccines | Phase 2 | 209 | Not forecastNo arm registered as a control |
| Jun 8, 2026 | A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)NCT06687967 · Dupilumab, Placebo | Sanofi | Other | Phase 3 | 142 | SealedSep 29, 2026 |
| Jun 8, 2026 | A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)NCT06687980 · Dupilumab, Placebo | Sanofi | Other | Phase 3 | 138 | SealedSep 29, 2026 |
| Jun 9, 2026 | Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)NCT06151197 · EN3835, Placebo | Endo USA Inc., a Keenova Therapeutics Company | Other | Phase 3 | 436 | SealedSep 29, 2026 |
| Jun 9, 2026 | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsNCT05048797 · Trastuzumab Deruxtecan, Cisplatin, Carboplatin | AstraZeneca | Oncology | Phase 3 | 454 | SealedSep 29, 2026 |
| Jun 9, 2026 | ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationNCT05021835 · Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B) | Novo Nordisk A/S | Cardiovascular | Phase 3 | 6,385 | SealedSep 29, 2026 |
| Jun 10, 2026 | An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)NCT06073132 · AC-203, Vehicle | TWi Biotechnology, Inc. | Other | Phase 2/3 | 80 | SealedSep 29, 2026 |
| Jun 10, 2026 | A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughNCT05600777 · BLU-5937, Placebo | Bellus Health Inc. - a GSK company | Other | Phase 3 | 997 | SealedSep 29, 2026 |
| Jun 10, 2026 | DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)NCT06539195 · DZD8586, DZD8586, DZD8586 | Dizal Pharmaceuticals | Oncology | Phase 2 | 59 | Not forecastNo arm registered as a control |
| Jun 10, 2026 | A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkNCT06290128 · Riliprubart, Placebo, Riliprubart | Sanofi | Neurology | Phase 3 | 109 | SealedSep 29, 2026 |
| Jun 10, 2026 | A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisNCT06407934 · Amlitelimab, Placebo | Sanofi | Immunology & inflammation | Phase 3 | 1,541 | SealedSep 29, 2026 |
| Jun 11, 2026 | Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress IncontinenceNCT03104517 · AMDC-USR (iltamiocel), Placebo | Cook MyoSite | Other | Phase 3 | 96 | SealedSep 29, 2026 |
| Jun 12, 2026 | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)NCT04895696 · Afimetoran, Placebo | Beeline Medicines Corporation | Immunology & inflammation | Phase 2 | 248 | SealedSep 29, 2026 |
| Jun 12, 2026 | Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaNCT06347003 · Plozasiran Injection, Placebo | Arrowhead Pharmaceuticals | Diabetes & obesity | Phase 3 | 446 | SealedSep 29, 2026 |
| Jun 12, 2026 | A Clinical Trial of MT200605 for the Treatment of Acute Ischemic StrokeNCT07205328 · MT200605, MT200605, MT200605 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Cardiovascular | Phase 2 | 360 | SealedSep 29, 2026 |
| Jun 12, 2026 | A Study of GR1802 in Participants With Chronic Sinusitis With Nasal PolypsNCT06516302 · GR1802, Placebo | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Respiratory | Phase 3 | 228 | SealedSep 29, 2026 |
| Jun 12, 2026 | A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety DisorderNCT06809179 · Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray | VistaGen Therapeutics, Inc. | Psychiatry | Phase 2 | 61 | Not forecastNo arm registered as a control |
| Jun 12, 2026 | A Study of TLC590 for Postsurgical Pain Following BunionectomyNCT07222748 · TLC590, Liposomal Bupivacaine, Saline Placebo | TLC Biopharmaceuticals, Inc. | Pain | Phase 3 | 304 | SealedSep 30, 2026 |
| Jun 12, 2026 | A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial CystitisNCT06752603 · ONO-1110, Placebo | Ono Pharmaceutical Co., Ltd. | Other | Phase 2 | 57 | SealedSep 29, 2026 |
| Jun 14, 2026 | A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep DisturbancesNCT06685965 · RE03, Placebo | Reconnect Labs | Psychiatry | Phase 2 | 12 | SealedSep 29, 2026 |
| Jun 15, 2026 | Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughNCT06504446 · NOC-110, Placebo | Nocion Therapeutics | Other | Phase 2 | 455 | SealedSep 29, 2026 |
| Jun 15, 2026 | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)NCT05298423 · pembrolizumab/vibostolimab, durvalumab, cisplatin | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 610 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 15, 2026 | A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in AdultsNCT06742281 · CVXGA (CVXGA50), COMIRNATY® | CyanVac LLC | Infectious disease & vaccines | Phase 2 | 432 | SealedSep 29, 2026 |
| Jun 15, 2026 | A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic StrokeNCT05953480 · Redasemtide, Placebo | Shionogi | Cardiovascular | Phase 2 | 680 | SealedSep 29, 2026 |
| Jun 16, 2026 | A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · Retatrutide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 1,152 | SealedSep 29, 2026 |
| Jun 16, 2026 | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.NCT06383403 · Elafibranor, Placebo | Ipsen | Liver | Phase 3 | 92 | SealedSep 29, 2026 |
| Jun 16, 2026 | A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05692492 · ZSP1601, ZSP1601, Placebo | Guangdong Raynovent Biotech Co., Ltd | Liver | Phase 2 | 180 | SealedSep 29, 2026 |
| Jun 16, 2026 | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098 · Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab | Regeneron Pharmaceuticals | Diabetes & obesity | Phase 2 | 1,005 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 16, 2026 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940 · XL092, Atezolizumab, Regorafenib | Exelixis | Oncology | Phase 3 | 901 | SealedSep 29, 2026 |
| Jun 17, 2026 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)NCT04768972 · ION363, Placebo | Ionis Pharmaceuticals, Inc. | Oncology | Phase 3 | 89 | SealedSep 29, 2026 |
| Jun 17, 2026 | Vaginal Photobiomodulation for Chronic Pelvic PainNCT06673108 · SoLa Pelvic Therapy, Sham | SoLa Pelvic Therapy | Pain | Phase 2 | 128 | SealedSep 29, 2026 |
| Jun 17, 2026 | Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureNCT06935409 · HS-20093, Gemcitabine combined with docetaxel | Hansoh BioMedical R&D Company | Oncology | Phase 3 | 122 | SealedSep 29, 2026 |
| Jun 17, 2026 | A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) LesionsNCT07275814 · HRS-9231 Injection, Gadobutrol Injection, Magnetic Resonance Imaging (MRI) | Shanghai Shengdi Pharmaceutical Co., Ltd | Other | Phase 3 | 250 | Not forecastNot a treatment or prevention trial |
| Jun 17, 2026 | Study of Plozasiran in Adults With Severe HypertriglyceridemiaNCT06347016 · Plozasiran Injection, Placebo | Arrowhead Pharmaceuticals | Diabetes & obesity | Phase 3 | 311 | SealedSep 29, 2026 |
| Jun 17, 2026 | Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)NCT07811882 · KAE609 (Cipargamin), SoC (Coartem), INE963 | Novartis Pharmaceuticals | Infectious disease & vaccines | Phase 2 | 95 | SealedSep 29, 2026 |
| Jun 18, 2026 | Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD SubjectsNCT07024212 · DR10624 Injection, Placebo | Zhejiang Doer Biologics Co., Ltd. | Liver | Phase 2 | 110 | Not forecastNo arm registered as a control |
| Jun 18, 2026 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVNCT06868264 · Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL) | Atea Pharmaceuticals, Inc. | Infectious disease & vaccines | Phase 3 | 940 | SealedSep 29, 2026 |
| Jun 18, 2026 | A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）NCT04587908 · TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort], Placebo [Ambulatory Cohort] only | Taiho Pharmaceutical Co., Ltd. | Rare genetic disease | Phase 3 | 104 | SealedSep 29, 2026 |
| Jun 18, 2026 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)NCT04567550 · ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3 | AbbVie | Ophthalmology | Phase 2 | 139 | SealedSep 29, 2026 |
| Jun 19, 2026 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaNCT06425302 · Golcadomide, Rituximab, Cyclophosphamide | Celgene | Oncology | Phase 2 | 95 | Not forecastNo arm registered as a control |
| Jun 19, 2026 | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerNCT05217446 · Encorafenib, Cetuximab, Pembrolizumab | Pfizer | Oncology | Phase 2 | 108 | SealedSep 29, 2026 |
| Jun 20, 2026 | STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's DiseaseNCT05843578 · AGMB-129, Placebo | Agomab Spain S.L.U. | Immunology & inflammation | Phase 2 | 103 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 22, 2026 | A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot OsteomyelitisNCT05539963 · STIMULAN VG, Systemic Antibiotics | Biocomposites Ltd | Diabetes & obesity | Phase 2 | 61 | SealedSep 29, 2026 |
| Jun 22, 2026 | Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)NCT04336722 · Odevixibat, Placebo | Albireo, an Ipsen Company | Liver | Phase 3 | 254 | SealedSep 29, 2026 |
| Jun 22, 2026 | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy VolunteersNCT07560150 · I004, NovoLog | Amphastar Pharmaceuticals, Inc. | Other | Phase 2/3 | 62 | SealedSep 29, 2026 |
| Jun 23, 2026 | Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusNCT05966480 · Envudeucitinib, Placebo | Alumis Inc | Immunology & inflammation | Phase 2 | 408 | SealedSep 29, 2026 |
| Jun 23, 2026 | A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)NCT06643481 · VHB937, Placebo | Novartis Pharmaceuticals | Neurology | Phase 2 | 251 | SealedSep 29, 2026 |
| Jun 24, 2026 | A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate CancerNCT06395753 · Debio 4228 | Debiopharm International SA | Oncology | Phase 2 | 55 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 25, 2026 | Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive DisorderNCT07018245 · TJ0113, Placebo | Hangzhou PhecdaMed Co., Ltd. | Psychiatry | Phase 2 | 149 | SealedSep 29, 2026 |
| Jun 25, 2026 | A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive DisorderNCT06785012 · JNJ-89495120, Placebo | Janssen Research & Development, LLC | Psychiatry | Phase 2 | 105 | SealedSep 29, 2026 |
| Jun 25, 2026 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyNCT06440967 · Fezolinetant, Placebo, Tamoxifen | Astellas Pharma Global Development, Inc. | Oncology | Phase 3 | 982 | SealedSep 29, 2026 |
| Jun 25, 2026 | Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to TrikaftaNCT07108153 · SION-719, Placebo-to-match SION-719 | Sionna Therapeutics Inc. | Respiratory | Phase 2 | 15 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 26, 2026 | A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Novo Nordisk A/S | Diabetes & obesity | Phase 2 | 142 | SealedSep 29, 2026 |
| Jun 26, 2026 | Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to OsteoarthritisNCT06257537 · Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches | ZetrOZ, Inc. | Immunology & inflammation | Phase 2 | 307 | SealedSep 29, 2026 |
| Jun 26, 2026 | Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)NCT04505436 · HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | Liver | Phase 2 | 215 | SealedSep 29, 2026 |
| Jun 26, 2026 | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseNCT04711252 · AZD9833, Anastrozole, Anastrozole placebo | AstraZeneca | Oncology | Phase 3 | 1,371 | SealedSep 29, 2026 |
| Jun 26, 2026 | Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant WomenNCT07211152 · Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV, Vaxigrip QIV | Sinovac Biotech Co., Ltd | Infectious disease & vaccines | Phase 3 | 150 | SealedSep 29, 2026 |
| Jun 28, 2026 | A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes MellitusNCT07055386 · GZR102, GZR18 | Gan & Lee Pharmaceuticals. | Diabetes & obesity | Phase 2 | 90 | Not forecastNo arm registered as a control |
| Jun 28, 2026 | Study to Investigate Toothpaste on Antibacterial Effects in the Different Regions of the MouthNCT07458464 · stannous fluoride toothpaste, 0.76% Sodium Monofluorophosphate (Na MFP) toothpaste | Colgate Palmolive | Other | Phase 3 | 95 | SealedSep 29, 2026 |
| Jun 29, 2026 | A Phase 2b Study of Zagociguat in Patients With MELASNCT06402123 · zagociguat 15mg, zagociguat 30mg, Placebo | Tisento Therapeutics | Cardiovascular | Phase 2 | 43 | Not forecastNo arm registered as a control |
| Jun 29, 2026 | Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineNCT06806293 · Atogepant, Placebo for Atogepant | AbbVie | Neurology | Phase 3 | 468 | SealedSep 29, 2026 |
| Jun 29, 2026 | A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy AdultsNCT07047521 · Tetravalent Dengue Vaccine (TDV) | Takeda | Infectious disease & vaccines | Phase 3 | 496 | Not forecastNo arm registered as a control |
| Jun 29, 2026 | Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)NCT05531526 · AR1001, Placebo | AriBio Co., Ltd. | Neurology | Phase 3 | 1,535 | SealedSep 29, 2026 |
| Jun 29, 2026 | A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 DiabetesNCT07271251 · Oral semaglutide | Novo Nordisk A/S | Diabetes & obesity | Phase 3 | 267 | Not forecastNo arm registered as a control |
| Jun 30, 2026 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · Gedatolisib, Palbociclib, Fulvestrant | Celcuity Inc | Oncology | Phase 3 | 701 | SealedSep 29, 2026 |
| Jun 30, 2026 | Comparison of Standard vs. Accelerated Corneal CrosslinkingNCT03922542 · riboflavin 0.1%, Riboflavin 0.1% | Price Vision Group | Ophthalmology | Phase 2/3 | 508 | SealedSep 29, 2026 |
| Jun 30, 2026 | A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerNCT05353257 · HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy | Shanghai Henlius Biotech | Oncology | Phase 3 | 511 | SealedSep 29, 2026 |
| Jun 30, 2026 | A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)NCT06472076 · Dostarlimab, Belrestotug, Pembrolizumab | GlaxoSmithKline | Oncology | Phase 3 | 88 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 30, 2026 | A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell LymphomaNCT06485219 · 11.2 mg/m2 Purinostat Mesylate, 15 mg/m2 Purinostat Mesylate | Chengdu Zenitar Biomedical Technology Co., Ltd | Oncology | Phase 2 | 50 | Not forecastNo arm registered as a control |
| Jun 30, 2026 | A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal CancerNCT05652894 · HX008(Pucotenlimab), Investigator's Choice Chemotherapy | Taizhou Hanzhong biomedical co. LTD | Oncology | Phase 3 | 190 | SealedSep 29, 2026 |
| Jun 30, 2026 | Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.NCT04925024 · Lomecel-B medicinal signaling cells | Longeveron Inc. | Cardiovascular | Phase 2 | 40 | SealedSep 29, 2026 |
| Jun 30, 2026 | A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)NCT05786573 · Obexelimab, Obexelimab, Placebo | Zenas BioPharma (USA), LLC | Hematology | Phase 3 | 134 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 30, 2026 | A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRPNCT04850118 · rAAV2tYF-GRK1-hRPGRco, Control | Beacon Therapeutics | Ophthalmology | Phase 2/3 | 85 | SealedSep 29, 2026 |
| Jun 30, 2026 | A Phase 2 in Adult Subjects With Hereditary AngioedemaNCT06846398 · BW-20805, BW-20805, BW-20805 | Shanghai Argo Biopharmaceutical Co., Ltd. | Other | Phase 2 | 25 | Not forecastNo arm registered as a control |
| Jun 30, 2026 | Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and OlderNCT05304351 · Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix | Curevo Inc | Infectious disease & vaccines | Phase 2 | 1,516 | SealedSep 30, 2026 |
| Jun 30, 2026 | LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFNCT05983250 · TNX-103, Placebo | Tenax Therapeutics, Inc. | Cardiovascular | Phase 3 | 230 | SealedSep 29, 2026 |
| Jun 30, 2026 | A Study in Patients With Mixed DyslipidemiaNCT06497127 · BW-00112 | Shanghai Argo Biopharmaceutical Co., Ltd. | Cardiovascular | Phase 2 | 145 | Not forecastNo arm registered as a control |
| Jun 30, 2026 | Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After ChemotherapyNCT06711523 · PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.), PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.) | Kexing Biopharm Co., Ltd. | Oncology | Phase 3 | 250 | SealedSep 29, 2026 |
| Jul 2026 | A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH PatientsNCT06322628 · VSA006, Placebo | Visirna Therapeutics HK Limited | Liver | Phase 2 | 48 | SealedSep 29, 2026 |
| Jul 2026 | A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaNCT05943795 · SI-B001, Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 589 | Not forecastNo arm registered as a control |
| Jul 2026 | Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced MelanomaNCT04674683 · HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab | HUYABIO International, LLC. | Oncology | Phase 3 | 450 | SealedSep 29, 2026 |
| Jul 2026 | A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCNCT04736823 · AK112, Pemetrexed, Paclitaxel | Akeso | Oncology | Phase 2 | 265 | Not forecastNo arm registered as a control |
| Jul 1, 2026 | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571 · LY3841136, Tirzepatide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 2 | 367 | SealedSep 29, 2026 |
| Jul 2, 2026 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.NCT05523167 · EFG PH20 SC, PBO | argenx | Other | Phase 2/3 | 265 | SealedSep 29, 2026 |
| Jul 2, 2026 | A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionNCT07790120 · SAL0120, Placebo | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Cardiovascular | Phase 3 | 256 | SealedSep 29, 2026 |
| Jul 2, 2026 | A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)NCT06465303 · RTP-026, Placebo | ResoTher Pharma | Cardiovascular | Phase 2 | 66 | Not forecastNo arm registered as a control |
| Jul 2, 2026 | A Study With CIT-013 in RA PatientsNCT06567470 · CIT-013 low dose, CIT-013 high dose, Placebo | Citryll BV | Immunology & inflammation | Phase 2 | 96 | SealedSep 29, 2026 |
| Jul 5, 2026 | Clinical Investigation of Oral Malodor for Max Fresh Toothpaste Containing Zinc Citrate Versus a Commercially Available Regular Fluoride ToothpasteNCT07398378 · Max Fresh Toothpaste, Colgate Cavity Protection Toothpaste | Colgate Palmolive | Other | Phase 3 | 80 | SealedSep 29, 2026 |
| Jul 6, 2026 | A Study to Evaluate Solriktug in Adult Participants With AsthmaNCT06496607 · NSI-8226, NSI-8226, NSI-8226 | Uniquity One (UNI) | Respiratory | Phase 2 | 145 | SealedSep 29, 2026 |
| Jul 6, 2026 | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentNCT05261399 · Savolitinib, Osimertinib, Pemetrexed | AstraZeneca | Oncology | Phase 3 | 341 | SealedSep 29, 2026 |
| Jul 6, 2026 | A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804 · Tirzepatide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 2 | 134 | SealedSep 29, 2026 |
| Jul 7, 2026 | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsNCT06553547 · Tenapanor, Placebo | Ardelyx | Other | Phase 2 | 72 | SealedSep 29, 2026 |
| Jul 7, 2026 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyNCT04666610 · Brivaracetam, Placebo | UCB Biopharma SRL | Neurology | Phase 3 | 154 | Not forecastNo arm registered as a control |
| Jul 7, 2026 | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)NCT01983241 · Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP | Grifols Therapeutics LLC | Respiratory | Phase 3 | 345 | SealedSep 29, 2026 |
| Jul 8, 2026 | A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive DisorderNCT06254612 · SP-624, Placebo | Sirtsei Pharmaceuticals, Inc. | Psychiatry | Phase 2 | 497 | SealedSep 29, 2026 |
| Jul 8, 2026 | Avexitide for Treatment of Post-Bariatric HypoglycemiaNCT06747468 · Avexitide, Placebo | Amylyx Pharmaceuticals Inc. | Diabetes & obesity | Phase 3 | 75 | SealedSep 29, 2026 |
| Jul 9, 2026 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaNCT04039607 · Nivolumab, Ipilimumab, Sorafenib | Bristol-Myers Squibb | Oncology | Phase 3 | 732 | SealedSep 29, 2026 |
| Jul 9, 2026 | Phase 2 Study of MWN109 Tablet in Participants With Overweight or ObesityNCT07791524 · MWN109 1, MWN109 2, MWN109 3 | Shanghai Minwei Biotechnology Co., Ltd | Diabetes & obesity | Phase 2 | 255 | SealedSep 29, 2026 |
| Jul 10, 2026 | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesNCT06564844 · Datopotamab Deruxtecan, Rilvegostomig, Carboplatin | AstraZeneca | Oncology | Phase 3 | 25 | SealedSep 29, 2026 |
| Jul 13, 2026 | A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.NCT06720896 · APT-001 topical ophthalmic ointment (spinosad), Vehicle control for APT-001 topical ophthalmic ointment | Aperta Biosciences, LLC | Other | Phase 2 | 66 | SealedSep 29, 2026 |
| Jul 13, 2026 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56NCT06668064 · EYP-1901, Aflibercept (2.0 mg) | EyePoint Pharmaceuticals, Inc. | Ophthalmology | Phase 3 | 400 | SealedSep 29, 2026 |
| Jul 14, 2026 | The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With DepressionNCT06827431 · Ammoxetine, Ammoxetine, Placebo | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Psychiatry | Phase 3 | 786 | SealedSep 29, 2026 |
| Jul 14, 2026 | Safety and Efficacy of ABP-745 in Participants With an Acute Gout FlareNCT07145229 · ABP-745 Dose A, ABP-745 Dose B, Colchicine | Atom Therapeutics Co., Ltd | Immunology & inflammation | Phase 2 | 479 | SealedSep 29, 2026 |
| Jul 14, 2026 | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLNCT05164341 · metreleptin, Placebo | Chiesi Farmaceutici S.p.A. | Other | Phase 3 | 69 | SealedSep 29, 2026 |
| Jul 14, 2026 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisNCT06254950 · TAK-279, Placebo | Takeda | Immunology & inflammation | Phase 2 | 213 | SealedSep 29, 2026 |
| Jul 14, 2026 | A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMENCT06571045 · Ranibizumab, Remigromig | EyeBiotech Ltd. | Ophthalmology | Phase 2/3 | 984 | SealedSep 29, 2026 |
| Jul 14, 2026 | Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in AdultsNCT07446309 · HRS-9190; under Inhalational Anesthesia, HRS-9190; under Intravenous Anesthesia, Cisatracurium (under Inhalational Anesthesia). | Jiangsu HengRui Medicine Co., Ltd. | Other | Phase 2 | 67 | SealedSep 29, 2026 |
| Jul 14, 2026 | A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaNCT06748053 · GSK5784283, Placebo | GlaxoSmithKline | Respiratory | Phase 2 | 307 | Not forecastNo arm registered as a control |
| Jul 14, 2026 | ELAPR002f Injectable Gel in the Treatment of Atrophic Acne ScarsNCT05995340 · ELAPR002f Injectable Gel, Saline Active Control | AbbVie | Other | Phase 3 | 157 | Not forecastNo arm registered as a control |
| Jul 14, 2026 | Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisNCT05583227 · Tezepelumab, Tezepelumab, Placebo | AstraZeneca | Other | Phase 3 | 368 | SealedSep 29, 2026 |
| Jul 15, 2026 | A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerNCT06057610 · SHR-A1811 Injection, SHR-A1811 Injection ； Pertuzumab Injection, Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection | Jiangsu HengRui Medicine Co., Ltd. | Oncology | Phase 3 | 868 | SealedSep 29, 2026 |
| Jul 15, 2026 | Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle WeaknessNCT06600581 · IMM01-STEM, Placebo, IMM01-STEM alternating with placebo (saline) | Immunis, Inc. | Diabetes & obesity | Phase 2 | 55 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 15, 2026 | A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)NCT06741228 · Placebo, DT120 | Definium Therapeutics US, Inc. | Psychiatry | Phase 3 | 214 | SealedSep 29, 2026 |
| Jul 15, 2026 | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT05814627 · Upadacitinib, Adalimumab, Upadacitinib Matching Placebo | AbbVie | Immunology & inflammation | Phase 3 | 487 | Not forecastNo arm registered as a control |
| Jul 15, 2026 | A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone BlockadeNCT07459166 · Naloxone Hydrochloride, Fentanyl, Sterile Saline | Clear Scientific, Inc. | Other | Phase 2 | 16 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 15, 2026 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT05152147 · Zanidatamab, Tislelizumab, Trastuzumab | Jazz Pharmaceuticals | Oncology | Phase 3 | 920 | SealedSep 29, 2026 |
| Jul 15, 2026 | Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV)NCT07774364 · AT-004, Placebo | Arctic Therapeutics | Other | Phase 2 | 63 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 16, 2026 | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDNCT04023552 · TQJ230, Placebo | Novartis Pharmaceuticals | Cardiovascular | Phase 3 | 8,323 | SealedSep 29, 2026 |
| Jul 17, 2026 | Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)NCT06940141 · Rademikibart in prefilled syringe, Matching placebo in prefilled syringe | Connect Biopharm LLC | Respiratory | Phase 2 | 160 | SealedSep 29, 2026 |
| Jul 18, 2026 | A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesNCT06649344 · HRS9531 Injection, Semaglutide Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Diabetes & obesity | Phase 3 | 884 | SealedSep 29, 2026 |
| Jul 20, 2026 | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus DiseaseNCT07220109 · RSVPreF3 OA vaccine, Placebo | GlaxoSmithKline | Infectious disease & vaccines | Phase 3 | 750 | SealedSep 29, 2026 |
| Jul 21, 2026 | A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years OldNCT02616302 · Dexlansoprazole | Takeda | Other | Phase 2 | 71 | Not forecastNo arm registered as a control |
| Jul 21, 2026 | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)NCT05147220 · Remibrutinib, Teriflunomide | Novartis Pharmaceuticals | Neurology | Phase 3 | 1,000 | SealedSep 29, 2026 |
| Jul 21, 2026 | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · Orforglipron, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 712 | SealedSep 29, 2026 |
| Jul 21, 2026 | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAENCT06669754 · Deucrictibant, Placebo | Pharvaris Netherlands B.V. | Other | Phase 3 | 85 | Not forecastNo arm registered as a control |
| Jul 22, 2026 | A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic DermatitisNCT06863961 · Afimkibart, Placebo | Hoffmann-La Roche | Immunology & inflammation | Phase 2 | 162 | SealedSep 29, 2026 |
| Jul 22, 2026 | Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCINCT05758896 · Isuzinaxib (APX-115), Placebo | Aptabio Therapeutics, Inc. | Kidney | Phase 2 | 218 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 22, 2026 | Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)NCT06101329 · Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Gilead Sciences | Infectious disease & vaccines | Phase 2 | 253 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 22, 2026 | Effect of Testofen on Erectile Function in an Adult Male PopulationNCT05232279 · Testofen 300mg, Testofen 600mg, Placebo comparator | RDC Clinical Pty Ltd | Other | Phase 3 | 64 | SealedSep 29, 2026 |
| Jul 22, 2026 | Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionNCT07354516 · QLS-111-FDC, Latanoprost (0.005%) | Qlaris Bio, Inc. | Ophthalmology | Phase 2/3 | 64 | SealedSep 29, 2026 |
| Jul 22, 2026 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyNCT04543617 · Tiragolumab, Atezolizumab, Tiragolumab Matching Placebo | Hoffmann-La Roche | Oncology | Phase 3 | 760 | SealedSep 29, 2026 |
| Jul 22, 2026 | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)NCT05156281 · Remibrutinib, Teriflunomide | Novartis Pharmaceuticals | Neurology | Phase 3 | 1,007 | SealedSep 29, 2026 |
| Jul 23, 2026 | Global Study of Del-desiran for the Treatment of DM1NCT06411288 · AOC 1001 (del-desiran), Placebo | Avidity Biosciences, Inc. | Other | Phase 3 | 159 | SealedSep 29, 2026 |
| Jul 23, 2026 | A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityNCT06104124 · Dazodalibep, Placebo | Amgen | Immunology & inflammation | Phase 3 | 651 | SealedSep 29, 2026 |
| Jul 23, 2026 | A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07281937 · VRB-101, Placebo | Verdiva Bio Dev Limited | Diabetes & obesity | Phase 2 | 206 | SealedSep 29, 2026 |
| Jul 23, 2026 | Phase 2b Study of EVO756 in Adults With Atopic DermatitisNCT07150845 · EVO756, EVO756, EVO756 | Evommune, Inc. | Immunology & inflammation | Phase 2 | 121 | SealedSep 29, 2026 |
| Jul 24, 2026 | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsNCT06067230 · mRNA-1345 | ModernaTX, Inc. | Infectious disease & vaccines | Phase 3 | 1,153 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 27, 2026 | A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDDNCT06236880 · GM-2505 | AbbVie | Psychiatry | Phase 2 | 126 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 27, 2026 | D9319C00001- 1L OC Mono Global RCTNCT04884360 · Olaparib, Matching placebo | AstraZeneca | Oncology | Phase 3 | 366 | SealedSep 29, 2026 |
| Jul 27, 2026 | Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)NCT06101342 · Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Infectious disease & vaccines | Phase 2 | 181 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 28, 2026 | Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2NCT05555589 · RGN-259, Placebo | ReGenTree, LLC | Other | Phase 3 | 70 | SealedSep 29, 2026 |
| Jul 30, 2026 | RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513 · Pemvidutide, Placebo | Altimmune, Inc. | Diabetes & obesity | Phase 2 | 100 | SealedSep 29, 2026 |
| Jul 30, 2026 | A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExerciseNCT06777238 · GZR18, Placebo | Gan & Lee Pharmaceuticals. | Diabetes & obesity | Phase 3 | 274 | SealedSep 29, 2026 |
| Jul 30, 2026 | Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)NCT06940154 · Rademikibart in prefilled syringe, Matching placebo in prefilled syringe | Connect Biopharm LLC | Respiratory | Phase 2 | 159 | SealedSep 29, 2026 |
| Jul 30, 2026 | A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)NCT06524830 · VLS-01-203 BU, VLS-01-BU Placebo | atai Therapeutics, Inc. | Psychiatry | Phase 2 | 142 | SealedSep 29, 2026 |
| Jul 30, 2026 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular CarcinomaNCT05320692 · TACE+Camrelizumab+Apatinib mesylate, TACE | Jiangsu HengRui Medicine Co., Ltd. | Oncology | Phase 3 | 423 | SealedSep 29, 2026 |
| Jul 30, 2026 | A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative ColitisNCT07035041 · D-2570, Placebo | InventisBio Co., Ltd | Immunology & inflammation | Phase 2 | 120 | SealedSep 29, 2026 |
| Jul 31, 2026 | SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerNCT05445908 · SKB264, KL-A167 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Oncology | Phase 2 | 184 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 31, 2026 | A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsNCT03253263 · OHB-607 | OHB Neonatology Ltd. | Ophthalmology | Phase 2 | 295 | SealedSep 29, 2026 |
| Jul 31, 2026 | Phase 3 Study of KP-100LI in Subjects With Vocal Fold ScarNCT05627648 · KP-100LI, Placebo | Kringle Pharma, Inc. | Other | Phase 3 | 62 | SealedSep 29, 2026 |
| Jul 31, 2026 | A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseaseNCT06881836 · ONO-2020, Placebo | Ono Pharmaceutical Co., Ltd. | Neurology | Phase 2 | 260 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 31, 2026 | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationNCT04639180 · Camrelizumab, Rivoceranib (Apatinib) | Jiangsu HengRui Medicine Co., Ltd. | Oncology | Phase 3 | 687 | SealedSep 29, 2026 |
| Jul 31, 2026 | Determining the Potential for Efficacy of OTX-601 in Reducing PTSD SymptomsNCT07316088 · OTX-601 Digital Therapeutic, OTX-003 Comparator app | Oui Therapeutics, Inc. | Psychiatry | Phase 2 | 40 | SealedSep 29, 2026 |
| Aug 2026 | Study of VYD2311 for the Prevention of COVID-19NCT07298434 · VYD2311-SD, VYD2311-MD, Placebo | Invivyd, Inc. | Infectious disease & vaccines | Phase 3 | 1,770 | SealedSep 29, 2026 |
| Aug 2026 | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.NCT03539744 · Pomalidomide, Dexamethasone, Venetoclax | AbbVie | Oncology | Phase 3 | 265 | SealedSep 29, 2026 |
| Aug 2026 | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)NCT07298330 · Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg | Mirum Pharmaceuticals, Inc. | Infectious disease & vaccines | Phase 3 | 80 | SealedSep 29, 2026 |
| Aug 2026 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)NCT06343948 · BL-B01D1, Eribulin, Vinorelbine | Sichuan Baili Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 383 | Not forecastNo arm registered as a control |
| Aug 2026 | A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)NCT06382116 · BL-B01D1, Pemetrexed+Cisplatin or Carboplatin | Sichuan Baili Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 432 | Not forecastNo arm registered as a control |
| Aug 2026 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor ComplicationsNCT06553027 · CVN424 75 mg, CVN424 150 mg, Placebo | Cerevance | Neurology | Phase 3 | 330 | SealedSep 29, 2026 |
| Aug 2026 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)NCT04514653 · Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2 | AbbVie | Ophthalmology | Phase 2 | 146 | SealedSep 29, 2026 |
| Aug 1, 2026 | A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)NCT06767735 · GZR4, Insulin Glargine U100 | Gan & Lee Pharmaceuticals. | Diabetes & obesity | Phase 3 | 580 | SealedSep 29, 2026 |
| Aug 2, 2026 | Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)NCT06829329 · AHB-137, NAs, Placebo | Ausper Biopharma Co., Ltd. | Infectious disease & vaccines | Phase 2 | 105 | Not forecastNo arm registered as a control |
| Aug 3, 2026 | A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT06598943 · Eltrekibart, Mirikizumab, Placebo | Eli Lilly and Company | Immunology & inflammation | Phase 2 | 143 | Not forecastNo arm registered as a control |
| Aug 3, 2026 | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)NCT06465186 · Efinopegdutide, Placebo | Merck Sharp & Dohme LLC | Liver | Phase 2 | 85 | SealedSep 29, 2026 |
| Aug 3, 2026 | A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)NCT07216482 · Enlicitide, Rosuvastatin, Placebo for Enlicitide | Merck Sharp & Dohme LLC | Cardiovascular | Phase 3 | 996 | SealedSep 29, 2026 |
| Aug 3, 2026 | Efficacy and Safety of CP006 Inhalation Powder in Participants With AsthmaNCT07807007 · Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol Fumarate | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | Respiratory | Phase 2 | 150 | SealedSep 29, 2026 |
| Aug 4, 2026 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)NCT06455202 · barzolvolimab, Matching placebo | Celldex Therapeutics | Immunology & inflammation | Phase 3 | 976 | Not forecastNo arm registered as a control |
| Aug 5, 2026 | A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)NCT07210463 · NT 201, NT 201 Placebo | Merz Aesthetics GmbH | Other | Phase 3 | 300 | SealedSep 29, 2026 |
| Aug 5, 2026 | A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDGNCT06892288 · GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label) | Glycomine, Inc. | Other | Phase 2/3 | 50 | SealedSep 29, 2026 |
| Aug 5, 2026 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderNCT07046494 · RAP-219, Placebo | Rapport Therapeutics Inc. | Psychiatry | Phase 2 | 253 | SealedSep 29, 2026 |
| Aug 5, 2026 | A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and PlaceboNCT07241377 · life'sTM omega O1035DS nTG, life'sTM omega O3020DS nTG, MEG-3 3323rTG | RDC Clinical Pty Ltd | Other | Phase 3 | 120 | Not forecastNot a treatment or prevention trial |
| Aug 5, 2026 | A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac DiseaseNCT06557772 · Amlitelimab, Placebo, SIGE | Sanofi | Other | Phase 2 | 229 | SealedSep 29, 2026 |
| Aug 6, 2026 | A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and InfantsNCT06213506 · iNTS-GMMA Dose C, iNTS-GMMA Dose B, iNTS-GMMA Dose A | GlaxoSmithKline | Infectious disease & vaccines | Phase 2 | 180 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Aug 6, 2026 | NE3107 in Adults With Neurological Symptoms of Long COVIDNCT06847191 · NE3107, Placebo | BioVie Inc. | Infectious disease & vaccines | Phase 2 | 203 | SealedSep 29, 2026 |
| Aug 6, 2026 | A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis SubjectsNCT07357831 · MC2-01 cream, MC2-01 vehicle, CAL/BDP Gel | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Immunology & inflammation | Phase 3 | 539 | SealedSep 29, 2026 |
| Aug 7, 2026 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisNCT06832618 · Ruxolitinib, Vehicle Cream | Incyte Corporation | Immunology & inflammation | Phase 3 | 159 | SealedSep 29, 2026 |
| Aug 10, 2026 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNCT05211895 · Durvalumab, Domvanalimab, Placebo | AstraZeneca | Oncology | Phase 3 | 791 | SealedSep 29, 2026 |
| Aug 10, 2026 | A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678 · ASC30 tablets, Placebo | Ascletis Pharma (China) Co., Limited | Diabetes & obesity | Phase 2 | 100 | SealedSep 29, 2026 |
| Aug 10, 2026 | Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System AtrophyNCT06671938 · exidavnemab, Placebo Comparator | BioArctic AB | Neurology | Phase 2 | 38 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Aug 10, 2026 | Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyNCT06681324 · AZD7798, Placebo | AstraZeneca | Immunology & inflammation | Phase 2 | 24 | Not forecastNot a treatment or prevention trial |
| Aug 10, 2026 | Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.NCT05267613 · Nexium 20mg, Nexium 10mg | AstraZeneca | Other | Phase 3 | 53 | SealedSep 29, 2026 |
| Aug 11, 2026 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)NCT06433219 · Tuvusertib (M1774), Niraparib, Lartesertib (M4076) | EMD Serono Research & Development Institute, Inc. | Oncology | Phase 2 | 63 | Not forecastNo arm registered as a control |
| Aug 11, 2026 | Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel DentifriceNCT07215767 · Stannous fluoride and Potassium nitrate Dentifrice, Stannous fluoride Dentifrice, Potassium nitrate Dentifrice | HALEON | Other | Phase 3 | 688 | SealedSep 29, 2026 |
| Aug 12, 2026 | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisNCT06901505 · Erythropoiesis-Stimulating Agent (ESA), Vadadustat | Akebia Therapeutics | Kidney | Phase 3 | 353 | SealedSep 29, 2026 |
| Aug 12, 2026 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaNCT06445023 · barzolvolimab, Matching placebo | Celldex Therapeutics | Immunology & inflammation | Phase 3 | 963 | Not forecastNo arm registered as a control |
| Aug 12, 2026 | A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)NCT06052059 · IV Tulisokibart, IV Placebo, SC Tulisokibart | Merck Sharp & Dohme LLC | Immunology & inflammation | Phase 3 | 1,109 | SealedSep 29, 2026 |
| Aug 12, 2026 | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)NCT06018337 · DB-1303/BNT323, Capecitabine, Paclitaxel | DualityBio Inc. | Oncology | Phase 3 | 541 | SealedSep 29, 2026 |
| Aug 12, 2026 | Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal CandidiasisNCT07109869 · Boric acid, Placebo | pH-D Feminine Health LLC | Other | Phase 3 | 333 | SealedSep 29, 2026 |
| Aug 12, 2026 | A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects With DMENCT06708260 · ENN0403, low dose, ENN0403, high dose | EnnovaBio | Ophthalmology | Phase 2 | 60 | Not forecastNo arm registered as a control |
| Aug 13, 2026 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)NCT06809595 · Placebo, DT120 | Definium Therapeutics US, Inc. | Psychiatry | Phase 3 | 245 | SealedSep 29, 2026 |
| Aug 13, 2026 | Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 · Petrelintide, Placebo | Zealand Pharma | Diabetes & obesity | Phase 2 | 221 | SealedSep 29, 2026 |
| Aug 14, 2026 | The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive SurgeryNCT06507436 · Herombopag tablets, Herombopag placebo tablets | Jiangsu HengRui Medicine Co., Ltd. | Cardiovascular | Phase 3 | 127 | Not forecastNo arm registered as a control |
| Aug 14, 2026 | A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)NCT07372924 · Tegileridine Fumarate lnjection, Tegileridine Fumarate lnjection, Remifentanil Hydrochloride for Injection | Jiangsu HengRui Medicine Co., Ltd. | Other | Phase 2 | 121 | SealedSep 29, 2026 |
| Aug 14, 2026 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseaseNCT06926660 · Vicadrostat, Empagliflozin, Placebo matching vicadrostat | Boehringer Ingelheim | Kidney | Phase 2 | 492 | SealedSep 29, 2026 |
| Aug 15, 2026 | Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccineNCT07655180 · COVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline) | Invivyd, Inc. | Infectious disease & vaccines | Phase 3 | 210 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Aug 17, 2026 | Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)NCT07016412 · Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Diabetes & obesity | Phase 2 | 497 | SealedSep 29, 2026 |
| Aug 17, 2026 | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.NCT05984277 · Volrustomig, Pembrolizumab, Carboplatin | AstraZeneca | Oncology | Phase 3 | 895 | SealedOct 10, 2026 |
| Aug 17, 2026 | A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence SeizuresNCT06769659 · NPT 2042, Placebo | NeuroPro Therapeutics, Inc. | Neurology | Phase 2 | 14 | SealedSep 29, 2026 |
| Aug 17, 2026 | Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in ChildrenNCT03339128 · Eluxadoline, Placebo | AbbVie | Other | Phase 2 | 272 | Not forecastNo arm registered as a control |
| Aug 18, 2026 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerNCT06619236 · Rina-S, Paclitaxel, Topotecan | Genmab | Oncology | Phase 3 | 584 | SealedSep 29, 2026 |
| Aug 18, 2026 | FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerNCT06519370 · FDA018-ADC, Eribulin, Capecitabine | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 350 | SealedSep 29, 2026 |
| Aug 19, 2026 | A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationNCT05230537 · Iptacopan (LNP023), Placebo | Novartis Pharmaceuticals | Ophthalmology | Phase 2 | 168 | SealedSep 29, 2026 |
| Aug 19, 2026 | A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1NCT06694805 · CAB LA + RPV LA, Oral ART | ViiV Healthcare | Infectious disease & vaccines | Phase 3 | 326 | SealedSep 29, 2026 |
| Aug 20, 2026 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsNCT05643534 · Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Other | Phase 3 | 180 | SealedSep 29, 2026 |
| Aug 20, 2026 | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeNCT06050122 · Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib | Sol-Gel Technologies, Ltd. | Oncology | Phase 3 | 113 | SealedSep 29, 2026 |
| Aug 20, 2026 | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerNCT06498479 · HS-20093, Topotecan | Hansoh BioMedical R&D Company | Oncology | Phase 3 | 461 | SealedSep 29, 2026 |
| Aug 21, 2026 | A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseaseNCT07284381 · ABBV-444, REFRESH OPTIVE UD | AbbVie | Ophthalmology | Phase 3 | 261 | SealedSep 29, 2026 |
| Aug 21, 2026 | Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)NCT07220629 · NT-0796, Placebo | NodThera Ltd. (a Rezera company) | Diabetes & obesity | Phase 2 | 82 | SealedSep 30, 2026 |
| Aug 24, 2026 | A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441 · Fianlimab, Cemiplimab, Pemetrexed | Regeneron Pharmaceuticals | Oncology | Phase 2 | 195 | Not forecastNo arm registered as a control |
| Aug 24, 2026 | A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and AboveNCT07204964 · Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A) | GlaxoSmithKline | Infectious disease & vaccines | Phase 2 | 971 | SealedSep 29, 2026 |
| Aug 26, 2026 | Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisNCT06468956 · SHR-1819, Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | Immunology & inflammation | Phase 3 | 652 | SealedSep 29, 2026 |
| Aug 27, 2026 | Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 · Retatrutide, Semaglutide | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 1,250 | SealedSep 29, 2026 |
| Aug 28, 2026 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyNCT05568095 · Domvanalimab, Zimberelimab, Capecitabine | Arcus Biosciences, Inc. | Oncology | Phase 3 | 1,040 | SealedSep 29, 2026 |
| Aug 28, 2026 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)NCT05522231 · fruquintinib+sintilimab, axitinib / everolimus, fruquintinib | Hutchmed | Oncology | Phase 2/3 | 265 | SealedSep 29, 2026 |
| Aug 30, 2026 | A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung CancerNCT07005336 · Uliledlimab, Sintilimab, Pemetrexed | TJ Biopharma Co., Ltd. | Oncology | Phase 2 | 150 | Not forecastNo arm registered as a control |
| Aug 30, 2026 | Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07108699 · HSK39004 Dry Powder Inhaler-0.75mg, HSK39004 Dry Powder Inhaler-1.5mg, HSK39004 Dry Powder Inhaler Simulant | Haisco Pharmaceutical Group Co., Ltd. | Respiratory | Phase 2 | 180 | Not forecastNo arm registered as a control |
| Aug 30, 2026 | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerNCT05446298 · ONC-392, Pembrolizumab | OncoC4, Inc. | Oncology | Phase 2 | 58 | Not forecastNo arm registered as a control |
| Aug 31, 2026 | Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) TrialNCT05408546 · TS23, Placebo | Translational Sciences, Inc. | Cardiovascular | Phase 2 | 64 | SealedSep 29, 2026 |
| Aug 31, 2026 | Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux DiseaseNCT07931521 · DW4421 20mg, DW4421 40mg, Esomeprazole 40mg | Daewon Pharmaceutical Co., Ltd. | Other | Phase 3 | 328 | SealedNov 13, 2026 |
| Aug 31, 2026 | A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65NCT07060885 · HDM SLIT-tablet (12 SQ-HDM), Placebo | ALK-Abelló A/S | Ophthalmology | Phase 3 | 327 | SealedSep 29, 2026 |
| Aug 31, 2026 | A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)NCT06081894 · Aficamten, Placebo | Cytokinetics | Cardiovascular | Phase 3 | 500 | SealedSep 29, 2026 |
| Aug 31, 2026 | A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)NCT05816252 · SKB264, Pembrolizumab, Carboplatin | Klus Pharma Inc. | Oncology | Phase 2 | 356 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Aug 31, 2026 | A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisNCT07225829 · 4P004, Placebo (NaCl 0.9%) | 4Moving Biotech | Immunology & inflammation | Phase 2 | 130 | SealedSep 29, 2026 |
| Aug 31, 2026 | Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)NCT06846515 · AR882 50 mg, AR882 75 mg, Placebo | Arthrosi Therapeutics | Immunology & inflammation | Phase 3 | 866 | SealedSep 29, 2026 |
| Aug 31, 2026 | LMN-201 for Prevention of C. Difficile Infection RecurrenceNCT05330182 · LMN-201, Placebo | Lumen Bioscience, Inc. | Infectious disease & vaccines | Phase 2/3 | 375 | SealedSep 29, 2026 |
| Aug 31, 2026 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)NCT06687369 · MB12 (Proposed Pembrolizumab Biosimilar), EU-sourced Keytruda®, US-sourced Keytruda® | mAbxience Research S.L. | Oncology | Phase 3 | 726 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Aug 31, 2026 | A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaNCT06666855 · DE-117B Eye Drops, Latanoprost | Santen Pharmaceutical Co., Ltd. | Ophthalmology | Phase 3 | 345 | SealedSep 29, 2026 |
| Aug 31, 2026 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)NCT04704934 · Trastuzumab deruxtecan, Ramucirumab, Paclitaxel | Daiichi Sankyo | Oncology | Phase 3 | 490 | SealedSep 29, 2026 |
| Sep 2026 | A Study of Obexelimab in Patients With Systemic Lupus ErythematosusNCT06559163 · Obexelimab, Placebo | Zenas BioPharma (USA), LLC | Immunology & inflammation | Phase 2 | 190 | SealedSep 29, 2026 |
| Sep 2026 | Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or ObesityNCT07804797 · MWN109 1, MWN109 2 | Shanghai Minwei Biotechnology Co., Ltd | Diabetes & obesity | Phase 2 | 71 | Not forecastNo arm registered as a control |
| Sep 2026 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyNCT06742190 · Empasiprubart, IVIG (Intravenous Immunoglobulin), Empasiprubart-placebo | argenx | Neurology | Phase 3 | 154 | SealedSep 29, 2026 |
| Sep 2026 | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06132256 · Axatilimab, Placebo | Syndax Pharmaceuticals | Respiratory | Phase 2 | 145 | SealedSep 29, 2026 |
| Sep 2026 | Taldefgrobep Alfa in Adults With Overweight and ObesityNCT07281495 · Taldefgrobep Alfa, Placebo, Taldefgrobep Alfa | Biohaven Therapeutics Ltd. | Diabetes & obesity | Phase 2 | 150 | SealedSep 29, 2026 |
| Sep 2026 | Monthly Dosing of Atacicept in IgANNCT07020923 · Atacicept | Vera Therapeutics, Inc. | Kidney | Phase 2 | 90 | Not forecastNo arm registered as a control |
| Sep 2026 | Clinical Study of Neflamapimod in Patients With Primary Progressive AphasiaNCT07033481 · Neflamapimod, Placebo | EIP Pharma Inc | Other | Phase 2 | 20 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 2026 | A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With HyperlipidemiaNCT07100418 · HRS-7249 Injection, Sodium Chloride Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Other | Phase 2 | 224 | SealedSep 29, 2026 |
| Sep 2026 | A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic CardiomyopathyNCT07021976 · HRS-1893 Tablets, HRS-1893 Placebo Tablets | Shandong Suncadia Medicine Co., Ltd. | Cardiovascular | Phase 3 | 228 | SealedSep 29, 2026 |
| Sep 2026 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870 · Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Other | Phase 2 | 112 | SealedSep 29, 2026 |
| Sep 2026 | Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.NCT05123755 · AV-001 Injection, AV-001 Placebo Injection | Vasomune Therapeutics, Inc. | Infectious disease & vaccines | Phase 2 | 60 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 2026 | A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye DiseaseNCT06088979 · TOUR006 - 20 MG, Placebo, TOUR006 - 50 MG | Tourmaline Bio, Inc., a Novartis Company | Ophthalmology | Phase 2 | 79 | SealedSep 29, 2026 |
| Sep 1, 2026 | Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus ChallengeNCT07059767 · ETH47, Placebo | Ethris GmbH | Respiratory | Phase 2 | 50 | SealedSep 29, 2026 |
| Sep 1, 2026 | A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisNCT06569056 · HRS-8427, Imipenem and Cilastatin Sodium, HRS-8427 placebo | Jiangsu HengRui Medicine Co., Ltd. | Kidney | Phase 3 | 579 | SealedSep 29, 2026 |
| Sep 1, 2026 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsNCT04824092 · Tafasitamab, Lenalidomide, Rituximab | Incyte Corporation | Oncology | Phase 3 | 899 | SealedSep 29, 2026 |
| Sep 2, 2026 | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKNCT06556368 · Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept | Kodiak Sciences Inc | Ophthalmology | Phase 3 | 667 | SealedSep 29, 2026 |
| Sep 2, 2026 | Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseNCT04691661 · Radotinib HCl 50 mg, Placebo | Il-Yang Pharm. Co., Ltd. | Neurology | Phase 2 | 43 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 3, 2026 | A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult ParticipantsNCT07032597 · HArmonyCa Lidocaine Injectable Gel, Restylane® Perlane® Lidocaine | AbbVie | Other | Phase 3 | 252 | SealedSep 29, 2026 |
| Sep 3, 2026 | A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityNCT06965413 · RO7204239, RO7204239 Matching Placebo, Tirzepatide | Hoffmann-La Roche | Diabetes & obesity | Phase 2 | 285 | SealedSep 29, 2026 |
| Sep 3, 2026 | A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With DyslipidaemiaNCT07218900 · Placebo, AZD0780, Rosuvastatin | AstraZeneca | Cardiovascular | Phase 2 | 76 | SealedSep 29, 2026 |
| Sep 4, 2026 | Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusNCT05039840 · SAR441344 IV, SAR441344 SC, Placebo IV | Sanofi | Immunology & inflammation | Phase 2 | 109 | SealedSep 29, 2026 |
| Sep 4, 2026 | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)NCT04652882 · Tasimelteon, Placebo | Vanda Pharmaceuticals | Other | Phase 3 | 43 | SealedSep 29, 2026 |
| Sep 4, 2026 | "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · CYB003, Psychological Support, Placebo | Cybin IRL Limited | Psychiatry | Phase 3 | 223 | SealedSep 29, 2026 |
| Sep 6, 2026 | Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated AdultsNCT07215520 · NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine | CastleVax Inc. | Infectious disease & vaccines | Phase 2 | 200 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 6, 2026 | IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaNCT07473960 · IBI306, placebo, placebo | Innovent Biologics (Suzhou) Co. Ltd. | Cardiovascular | Phase 3 | 198 | SealedSep 29, 2026 |
| Sep 7, 2026 | A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)NCT07176390 · Tulisokibart, Placebo, Methotrexate | Merck Sharp & Dohme LLC | Immunology & inflammation | Phase 2 | 185 | SealedSep 29, 2026 |
| Sep 7, 2026 | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesNCT05329766 · Domvanalimab, Quemliclustat, Zimberelimab | Arcus Biosciences, Inc. | Other | Phase 2 | 332 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 7, 2026 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)NCT03992430 · Eteplirsen | Sarepta Therapeutics, Inc. | Rare genetic disease | Phase 3 | 160 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 7, 2026 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)NCT05291091 · Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg | Edgewise Therapeutics, Inc. | Other | Phase 2 | 244 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 8, 2026 | Study of Bitopertin in Participants With EPP or XLP (APOLLO)NCT06910358 · Placebo, DISC-1459 | Disc Medicine, Inc | Other | Phase 3 | 183 | SealedSep 29, 2026 |
| Sep 9, 2026 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)NCT06741397 · CAB LA, New formulation of CAB LA | ViiV Healthcare | Infectious disease & vaccines | Phase 2 | 229 | Not forecastNot a treatment or prevention trial |
| Sep 9, 2026 | Aleniglipron Phase 2 Body Composition StudyNCT07169942 · aleniglipron or placebo | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Diabetes & obesity | Phase 2 | 71 | Not forecastNo arm registered as a control |
| Sep 9, 2026 | A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With SchizophreniaNCT07191483 · KYN-5356 low dose, Placebo, KYN-5356 Medium Dose | Kynexis B.V. | Psychiatry | Phase 2 | 149 | SealedSep 29, 2026 |
| Sep 9, 2026 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56NCT06683742 · EYP-1901, Aflibercept (2.0 mg) | EyePoint Pharmaceuticals, Inc. | Ophthalmology | Phase 3 | 400 | SealedSep 29, 2026 |
| Sep 10, 2026 | A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDNCT06208306 · Itepekimab (SAR440340), Placebo | Sanofi | Respiratory | Phase 3 | 669 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 10, 2026 | A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202NCT06062420 · Dostarlimab, Belrestotug, Nelistotug | GlaxoSmithKline | Oncology | Phase 2 | 316 | Not forecastNo arm registered as a control |
| Sep 11, 2026 | A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisNCT06431373 · Brepocitinib PO QD, Placebo PO QD | Priovant Therapeutics, Inc. | Ophthalmology | Phase 3 | 371 | SealedSep 29, 2026 |
| Sep 11, 2026 | A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksNCT06851559 · Vonoprazan, Placebo | Phathom Pharmaceuticals, Inc. | Other | Phase 2 | 95 | Not forecastNo arm registered as a control |
| Sep 15, 2026 | A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent WheezingNCT05857930 · OM-85, Placebo | OM Pharma SA | Other | Phase 2 | 296 | SealedSep 29, 2026 |
| Sep 15, 2026 | A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential HypertensionNCT07835971 · GW906, Placebo | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Cardiovascular | Phase 2 | 319 | SealedSep 29, 2026 |
| Sep 17, 2026 | A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsNCT06292923 · Foralumab, Placebo | Tiziana Life Sciences LTD | Neurology | Phase 2 | 54 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 17, 2026 | A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)NCT07074886 · Ocrelizumab Test Formulation, Ocrelizumab Reference Formulation | Hoffmann-La Roche | Neurology | Phase 2 | 193 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 17, 2026 | A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955 · Saline, QCZ484 | Novartis Pharmaceuticals | Cardiovascular | Phase 2 | 396 | Not forecastNot a treatment or prevention trial |
| Sep 17, 2026 | HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.NCT07233070 · HRS-7450 Injection, HRS-7450 Injection, HRS-7450 Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Cardiovascular | Phase 2 | 210 | SealedSep 29, 2026 |
| Sep 17, 2026 | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173 · Domvanalimab, Zimberelimab, Carboplatin | Arcus Biosciences, Inc. | Oncology | Phase 2 | 169 | SealedSep 29, 2026 |
| Sep 17, 2026 | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49NCT07284654 · 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 | Vaxcyte, Inc. | Other | Phase 3 | 4,049 | SealedSep 29, 2026 |
| Sep 18, 2026 | Aleniglipron Phase 2 in Type 2 Diabetes MellitusNCT07400588 · Aleniglipron, Placebo | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Diabetes & obesity | Phase 2 | 58 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 18, 2026 | A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusNCT06778967 · GZR18, semaglutide | Gan & Lee Pharmaceuticals. | Diabetes & obesity | Phase 3 | 1,133 | SealedSep 29, 2026 |
| Sep 18, 2026 | Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610 · Tibulizumab Dose A, Tibulizumab Dose B, Placebo | Zura Bio Inc | Immunology & inflammation | Phase 2 | 247 | SealedSep 29, 2026 |
| Sep 21, 2026 | Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289 · ICS-LABA, benralizumab, Placebo for Benralizumab | AstraZeneca | Respiratory | Phase 3 | 130 | SealedOct 17, 2026 |
| Sep 21, 2026 | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisNCT07011706 · ATI-045, Placebo | Aclaris Therapeutics, Inc. | Immunology & inflammation | Phase 2 | 110 | SealedSep 29, 2026 |
| Sep 22, 2026 | Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossNCT07292441 · GZR18 injection, Placebo | Gan & Lee Pharmaceuticals. | Diabetes & obesity | Phase 3 | 224 | SealedSep 29, 2026 |
| Sep 22, 2026 | A Trial of HRS-8427 in the Treatment of Adults With Bacterial PneumoniaNCT06841731 · HRS-8427, Meropenem | Jiangsu HengRui Medicine Co., Ltd. | Infectious disease & vaccines | Phase 2 | 120 | SealedSep 29, 2026 |
| Sep 22, 2026 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNCT04129502 · TAK-788, Pemetrexed, Cisplatin | Takeda | Oncology | Phase 3 | 354 | SealedSep 29, 2026 |
| Sep 22, 2026 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeNCT07300839 · BNT162b2 Vaccine, Placebo | BioNTech SE | Infectious disease & vaccines | Phase 3 | 5,240 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 22, 2026 | Effect of 10 mg Xanamem on Dementia Due to Alzheimer's DiseaseNCT06125951 · Xanamem, Placebo | Actinogen Medical | Neurology | Phase 2/3 | 247 | SealedSep 29, 2026 |
| Sep 23, 2026 | A Study to Evaluate Solrikitug in Participants With COPD (ZION)NCT06496620 · Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo | Uniquity One (UNI) | Respiratory | Phase 2 | 182 | Not forecastNo arm registered as a control |
| Sep 23, 2026 | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834347 · Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) | Sanofi | Respiratory | Phase 3 | 231 | SealedSep 29, 2026 |
| Sep 23, 2026 | A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT06937749 · Placebo, IBI362 | Innovent Biologics (Suzhou) Co. Ltd. | Liver | Phase 2 | 181 | SealedSep 29, 2026 |
| Sep 23, 2026 | A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic StrokeNCT06987643 · Neflamapimod, Placebo | EIP Pharma Inc | Cardiovascular | Phase 2 | 45 | SealedSep 29, 2026 |
| Sep 24, 2026 | A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908 · placebo, IBI362 | Innovent Biologics (Suzhou) Co. Ltd. | Diabetes & obesity | Phase 2 | 141 | SealedSep 29, 2026 |
| Sep 24, 2026 | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834360 · Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) | Sanofi | Respiratory | Phase 3 | 216 | SealedSep 29, 2026 |
| Sep 24, 2026 | Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis DNCT06649266 · RBD1016, Placebo | Ribocure Pharmaceuticals AB | Infectious disease & vaccines | Phase 2 | 14 | Not forecastNo arm registered as a control |
| Sep 26, 2026 | A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaNCT06942910 · Zibotentan/Dapagliflozin, Dapagliflozin | AstraZeneca | Kidney | Phase 2 | 224 | SealedSep 29, 2026 |
| Sep 27, 2026 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04961567 · Litifilimab, Placebo | Biogen | Immunology & inflammation | Phase 3 | 562 | SealedSep 29, 2026 |
| Sep 28, 2026 | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentNCT05133531 · Ravulizumab, Pozelimab, Cemdisiran | Regeneron Pharmaceuticals | Hematology | Phase 3 | 202 | Not forecastNo arm registered as a control |
| Sep 28, 2026 | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)NCT05552976 · Mezigdomide, Carfilzomib, Dexamethasone | Bristol-Myers Squibb | Oncology | Phase 3 | 606 | SealedSep 29, 2026 |
| Sep 28, 2026 | A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626 · OCU410ST | Ocugen | Ophthalmology | Phase 2/3 | 51 | SealedSep 29, 2026 |
| Sep 28, 2026 | Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral NutritionNCT06512584 · PJ009, PJ009 Placebo | Chongqing Peg-Bio Biopharm Co., Ltd. | Endocrine & bone | Phase 3 | 72 | SealedSep 29, 2026 |
| Sep 28, 2026 | A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)NCT07037875 · Linaprazan glurate 50 mg Twice Daily (BID), Linaprazan Glurate 50 mg Once Daily (QD), Lansoprazole 30 mg Once Daily (QD) | Cinclus Pharma Holding AB | Other | Phase 3 | 523 | SealedSep 29, 2026 |
| Sep 29, 2026 | Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)NCT05263934 · Depemokimab, Mepolizumab, Placebo matching mepolizumab | GlaxoSmithKline | Immunology & inflammation | Phase 3 | 163 | SealedSep 29, 2026 |
| Sep 29, 2026 | A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )NCT04849728 · IVA337, Placebo | Inventiva Pharma | Liver | Phase 3 | 1,000 | SealedSep 29, 2026 |
| Sep 30, 2026 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04895241 · Litifilimab, Placebo | Biogen | Immunology & inflammation | Phase 3 | 548 | SealedSep 29, 2026 |
| Sep 30, 2026 | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionNCT06903338 · Tobevibart, Elebsiran | Vir Biotechnology, Inc. | Infectious disease & vaccines | Phase 3 | 124 | Not forecastNo arm registered as a control |
| Sep 30, 2026 | Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT TrialNCT05372718 · Recombinant non-immunogenic staphylokinase (Fortelyzin®), surgical methods of treatment | Supergene, LLC | Cardiovascular | Phase 3 | 170 | Not forecastNo arm registered as a control |
| Sep 30, 2026 | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesNCT04603807 · Entrectinib, Crizotinib | Hoffmann-La Roche | Oncology | Phase 3 | 217 | SealedSep 29, 2026 |
| Sep 30, 2026 | Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)NCT07327840 · Kylo-11 or matched placebo | Kylonova (Xiamen) Biopharma co., LTD. | Other | Phase 2 | 204 | Not forecastNo arm registered as a control |
| Sep 30, 2026 | Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerNCT05116462 · Pemetrexed, Carboplatin, Paclitaxel | Innovent Biologics (Suzhou) Co. Ltd. | Oncology | Phase 3 | 506 | SealedSep 29, 2026 |
| Sep 30, 2026 | A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast CancerNCT07192588 · GR1014-CG 2.4%, Vehicle Gel, Radiation Therapy | Graegis Pharmaceuticals Ltd | Oncology | Phase 2 | 273 | Not forecastNot a treatment or prevention trial |
| Sep 30, 2026 | An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyNCT06534892 · RSVPreF3 OA vaccine | GlaxoSmithKline | Infectious disease & vaccines | Phase 3 | 10,212 | SealedSep 29, 2026 |
| Oct 2026 | Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With OverweightNCT07791537 · MWN109 1, MWN109 2, MWN109 3 | Shanghai Minwei Biotechnology Co., Ltd | Diabetes & obesity | Phase 2 | 125 | SealedSep 29, 2026 |
| Oct 2026 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379 · Azetukalner, Placebo | Xenon Pharmaceuticals Inc. | Psychiatry | Phase 3 | 450 | SealedSep 29, 2026 |
| Oct 2026 | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDNCT05407636 · ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) | AbbVie | Ophthalmology | Phase 3 | 735 | SealedSep 29, 2026 |
| Oct 2026 | A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerNCT06316531 · BL-M07D1, T-DM1 | Sichuan Baili Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 274 | Not forecastNo arm registered as a control |
| Oct 2026 | A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)NCT04088396 · Baricitinib, Tocilizumab | Eli Lilly and Company | Immunology & inflammation | Phase 3 | 58 | SealedSep 29, 2026 |
| Oct 2026 | Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic AlopeciaNCT05888922 · Minoxidil Tablets, Minoxidil Topical, Placebo oral tablet | Industrial Farmacéutica Cantabria, S.A. | Immunology & inflammation | Phase 3 | 520 | SealedSep 29, 2026 |
| Oct 2026 | A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)NCT06422884 · ENV-101, Placebo | Endeavor Biomedicines, Inc. | Respiratory | Phase 2 | 213 | SealedSep 29, 2026 |
| Oct 2026 | Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyNCT06309966 · BHV-7000, BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Neurology | Phase 2/3 | 390 | SealedSep 29, 2026 |
| Oct 2026 | A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)NCT06980805 · IMVT-1402, Placebo | Immunovant Sciences GmbH | Immunology & inflammation | Phase 2 | 56 | SealedSep 29, 2026 |
| Oct 2026 | A Study Evaluating TRIV-509 in Atopic DermatitisNCT07167758 · TRIV-509, Placebo | Triveni Bio | Immunology & inflammation | Phase 2 | 95 | Not forecastNo arm registered as a control |
| Oct 2026 | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerNCT06591520 · AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Akeso | Oncology | Phase 3 | 682 | SealedSep 29, 2026 |
| Oct 2026 | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)NCT06553768 · Maralixibat, Placebo | Mirum Pharmaceuticals, Inc. | Other | Phase 3 | 90 | SealedSep 29, 2026 |
| Oct 2026 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)NCT04965493 · Pirtobrutinib, Venetoclax, Rituximab | Loxo Oncology, Inc. | Oncology | Phase 3 | 600 | SealedSep 29, 2026 |
| Oct 2026 | Dazucorilant in Patients With Amyotrophic Lateral SclerosisNCT05407324 · Dazucorilant 300 mg, Dazucorilant 150 mg, Placebo | Corcept Therapeutics | Neurology | Phase 2 | 279 | SealedSep 29, 2026 |
| Oct 2026 | Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 · Retatrutide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 320 | SealedSep 29, 2026 |
| Oct 2026 | Evaluate the Safety and Efficacy of TJO-087NCT07810972 · TJO-087, TJO-087, Vehicle (Placebo solution) | Taejoon Pharmaceutical Co., Ltd. | Ophthalmology | Phase 2 | 90 | SealedSep 29, 2026 |
| Oct 1, 2026 | A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminNCT06257966 · Exendin-4 Fc fusion protein injection(1.2mg）, Exendin-4 Fc fusion protein injection（2.4mg）, Dulaglutide | Beijing Dongfang Biotech Co., Ltd. | Diabetes & obesity | Phase 3 | 600 | SealedSep 29, 2026 |
| Oct 1, 2026 | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNCT06200207 · Ziltivekimab, Placebo | Novo Nordisk A/S | Cardiovascular | Phase 3 | 673 | SealedSep 29, 2026 |
| Oct 1, 2026 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)NCT06958211 · Ruxolitinib Cream, Vehicle Cream | Incyte Corporation | Immunology & inflammation | Phase 3 | 573 | SealedSep 29, 2026 |
| Oct 1, 2026 | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseNCT06388564 · Axatilimab, Ruxolitinib, Corticosteroids | Incyte Corporation | Other | Phase 2 | 130 | Not forecastNo arm registered as a control |
| Oct 2, 2026 | A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac DiseaseNCT06807463 · TEV-53408, Placebo | Teva Branded Pharmaceutical Products R&D LLC | Other | Phase 2 | 50 | SealedSep 29, 2026 |
| Oct 4, 2026 | A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive KeratectomyNCT07412496 · Topical Ocular BL1332 low dose, Topical Ocular BL1332 high dose, BL1332 Vehicle ophthalmic vehicle | Bausch & Lomb Incorporated | Ophthalmology | Phase 2 | 130 | SealedSep 29, 2026 |
| Oct 5, 2026 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisNCT03165734 · Pacritinib, Physician's Choice medications | Swedish Orphan Biovitrum | Cardiovascular | Phase 3 | 407 | SealedSep 29, 2026 |
| Oct 5, 2026 | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaNCT05805501 · Tobemstomig, Tiragolumab, Pembrolizumab | Hoffmann-La Roche | Oncology | Phase 2 | 199 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 6, 2026 | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550 · furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy | ArriVent BioPharma, Inc. | Oncology | Phase 3 | 398 | SealedSep 29, 2026 |
| Oct 6, 2026 | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisNCT06003426 · BMS-986278, BMS-986278 Placebo | Bristol-Myers Squibb | Respiratory | Phase 3 | 1,255 | SealedSep 29, 2026 |
| Oct 12, 2026 | A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCNCT05884398 · Apalutamide, Androgen-deprivation Therapy (ADT) | Janssen Research & Development, LLC | Oncology | Phase 3 | 420 | SealedSep 29, 2026 |
| Oct 13, 2026 | Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPFNCT05389215 · DWN12088, Placebo | Daewoong Pharmaceutical Co. LTD. | Respiratory | Phase 2 | 102 | SealedSep 29, 2026 |
| Oct 14, 2026 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabNCT04770896 · Atezolizumab, Lenvatinib, Sorafenib | Hoffmann-La Roche | Oncology | Phase 3 | 557 | SealedSep 29, 2026 |
| Oct 15, 2026 | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKENCT05702034 · Milvexian, Placebo | Janssen Research & Development, LLC | Cardiovascular | Phase 3 | 12,523 | SealedSep 29, 2026 |
| Oct 15, 2026 | A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerNCT05852691 · Tobemstomig, Pembrolizumab, Nab-Paclitaxel | Hoffmann-La Roche | Oncology | Phase 2 | 83 | SealedSep 29, 2026 |
| Oct 15, 2026 | Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsNCT06569108 · KN057 | Suzhou Alphamab Co., Ltd. | Hematology | Phase 3 | 125 | Not forecastNo arm registered as a control |
| Oct 15, 2026 | MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) TrialNCT07505303 · ECC4703, Placebo, Semaglutide | Eccogene | Diabetes & obesity | Phase 2 | 151 | SealedSep 29, 2026 |
| Oct 18, 2026 | Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled CancersNCT07033585 · Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | Oncology | Phase 2/3 | 600 | Not forecastNot a treatment or prevention trial |
| Oct 19, 2026 | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)NCT05617677 · Deucravacitinib, Placebo | Bristol-Myers Squibb | Immunology & inflammation | Phase 3 | 516 | SealedSep 29, 2026 |
| Oct 19, 2026 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)NCT06516965 · Povorcitinib, Placebo | Incyte Corporation | Other | Phase 3 | 346 | SealedSep 29, 2026 |
| Oct 19, 2026 | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusNCT05620407 · Deucravacitinib, Placebo | Bristol-Myers Squibb | Immunology & inflammation | Phase 3 | 513 | SealedSep 29, 2026 |
| Oct 19, 2026 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)NCT06356311 · Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 473 | SealedSep 29, 2026 |
| Oct 19, 2026 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)NCT06516952 · Povorcitinib, Placebo | Incyte Corporation | Other | Phase 3 | 349 | SealedSep 29, 2026 |
| Oct 20, 2026 | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusNCT05531565 · Litifilimab, Placebo | Biogen | Immunology & inflammation | Phase 2/3 | 450 | SealedSep 29, 2026 |
| Oct 20, 2026 | A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaNCT06894212 · SEP-363856, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Psychiatry | Phase 3 | 538 | SealedSep 29, 2026 |
| Oct 21, 2026 | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07290569 · ORKA-001, Placebo | Oruka Therapeutics, Inc. | Immunology & inflammation | Phase 2 | 160 | SealedSep 29, 2026 |
| Oct 22, 2026 | A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateNCT06245408 · Dazodalibep, Placebo | Amgen | Immunology & inflammation | Phase 3 | 434 | SealedSep 29, 2026 |
| Oct 22, 2026 | A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)NCT06339008 · LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Respiratory | Phase 3 | 450 | SealedSep 29, 2026 |
| Oct 23, 2026 | This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightNCT07017179 · AZD6234, Placebo, AZD9550 | AstraZeneca | Diabetes & obesity | Phase 2 | 16 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 23, 2026 | Study on the Efficacy and Safety of QLM1016 in SchizophreniaNCT06799559 · 3-6mg QLM1016, 10-20 mg Aripiprazole oral solution film | Qilu Pharmaceutical Co., Ltd. | Psychiatry | Phase 3 | 402 | SealedSep 29, 2026 |
| Oct 24, 2026 | A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of MethamphetamineNCT06721494 · Methamphetamine, Sterile Saline, CS-1103 | Clear Scientific, Inc. | Other | Phase 2 | 34 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 26, 2026 | Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular EventsNCT05360446 · Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Cardiovascular | Phase 3 | 610 | SealedSep 29, 2026 |
| Oct 26, 2026 | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaNCT06664619 · Fp/ABS, FP, ABS | Teva Branded Pharmaceutical Products R&D LLC | Respiratory | Phase 3 | 649 | SealedSep 29, 2026 |
| Oct 26, 2026 | A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyNCT06722157 · BI 771716, Pegcetacoplan, Sham comparator to BI 771716 | Boehringer Ingelheim | Ophthalmology | Phase 2 | 202 | SealedSep 29, 2026 |
| Oct 26, 2026 | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerNCT05565378 · Pembrolizumab, Dostarlimab, Belrestotug | GlaxoSmithKline | Oncology | Phase 2 | 351 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 27, 2026 | Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionNCT02932150 · TAF, Placebo | Gilead Sciences | Infectious disease & vaccines | Phase 2 | 150 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 27, 2026 | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASNCT06008093 · Durvalumab, Tremelimumab, Pemetrexed | AstraZeneca | Oncology | Phase 2 | 103 | Not forecastNo arm registered as a control |
| Oct 28, 2026 | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)NCT05239728 · Belzutifan, Pembrolizumab, Placebo | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 1,800 | Not forecastNo arm registered as a control |
| Oct 29, 2026 | Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaNCT05928390 · Pasireotide Diaspartate | RECORDATI GROUP | Diabetes & obesity | Phase 2 | 93 | SealedSep 29, 2026 |
| Oct 29, 2026 | Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)NCT05653349 · Ianalumab, Placebo, Corticosteroids | Novartis Pharmaceuticals | Cardiovascular | Phase 3 | 226 | SealedSep 29, 2026 |
| Oct 29, 2026 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative ColitisNCT06588855 · Afimkibart, Placebo | Hoffmann-La Roche | Immunology & inflammation | Phase 3 | 350 | SealedSep 29, 2026 |
| Oct 29, 2026 | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173 · sabirnetug, Placebo | Acumen Pharmaceuticals | Neurology | Phase 2 | 542 | SealedSep 29, 2026 |
| Oct 29, 2026 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)NCT06959225 · Ruxolitinib Cream, Vehicle Cream | Incyte Corporation | Immunology & inflammation | Phase 3 | 580 | SealedSep 29, 2026 |
| Oct 30, 2026 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaNCT04657991 · Encorafenib, Binimetinib, Pembrolizumab | Pfizer | Oncology | Phase 3 | 257 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 30, 2026 | A Study of VCT220 in Participants With Hypertension and Obesity or OverweightNCT07360275 · VCT220 Tablet, VCT220 Placebo Tablet | Vincentage Pharma Co., Ltd | Diabetes & obesity | Phase 2 | 160 | SealedSep 29, 2026 |
| Oct 30, 2026 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)NCT05853575 · Adagrasib | Mirati Therapeutics Inc. | Oncology | Phase 2 | 200 | Not forecastNo arm registered as a control |
| Oct 30, 2026 | A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 DiabetesNCT07026968 · Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR | CSPC Ouyi Pharmaceutical Co., Ltd. | Diabetes & obesity | Phase 3 | 815 | SealedSep 29, 2026 |
| Oct 30, 2026 | Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerNCT04851613 · Afuresertib, Afuresertib/placebo | Laekna Limited | Oncology | Phase 3 | 256 | SealedSep 29, 2026 |
| Oct 31, 2026 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerNCT03816163 · zolbetuximab, nab-paclitaxel, gemcitabine | Astellas Pharma Global Development, Inc. | Oncology | Phase 2 | 393 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 31, 2026 | Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeNCT04842617 · SHR6390, placebo | Jiangsu HengRui Medicine Co., Ltd. | Oncology | Phase 3 | 5,274 | SealedSep 29, 2026 |
| Oct 31, 2026 | Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart FailureNCT05598333 · AB-1002 | AskBio Inc | Cardiovascular | Phase 2 | 150 | SealedSep 29, 2026 |
| Oct 31, 2026 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)NCT06719141 · LP352, Placebo | Longboard Pharmaceuticals | Neurology | Phase 3 | 367 | SealedSep 29, 2026 |
| Oct 31, 2026 | A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)NCT06593522 · anvumetostat | Amgen | Oncology | Phase 2 | 61 | Not forecastNo arm registered as a control |
| Oct 31, 2026 | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaNCT06116916 · KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Ophthalmology | Phase 2 | 185 | Not forecastNo arm registered as a control |
| Oct 31, 2026 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · Palazestrant, Fulvestrant, Anastrozole | Olema Pharmaceuticals, Inc. | Oncology | Phase 3 | 510 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 31, 2026 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633 · Ublituximab, Ublituximab | TG Therapeutics, Inc. | Neurology | Phase 3 | 360 | SealedSep 29, 2026 |
| Oct 31, 2026 | A Study of SPY072 in Rheumatic DiseaseNCT07148414 · SPY002-072, Placebo | Spyre Therapeutics, Inc. | Immunology & inflammation | Phase 2 | 285 | SealedSep 29, 2026 |
| Oct 31, 2026 | Study of JK07 in Patients With Chronic Heart FailureNCT06369298 · JK07, Placebo | Salubris Biotherapeutics Inc | Cardiovascular | Phase 2 | 282 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 2026 | Clinical Trial on Agitation in Alzheimer's DementiaNCT05543681 · IGC-AD1-Active, IGC-AD1-Placebo | IGC Pharma, LLC | Neurology | Phase 2 | 164 | SealedSep 29, 2026 |
| Nov 2026 | A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CFNCT06237335 · RCT2100, Placebo, RCT2100 | ReCode Therapeutics | Respiratory | Phase 2 | 128 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 2026 | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638 · IMU-838 tablets, Placebo matching IMU-838 tablets | Immunic AG | Neurology | Phase 3 | 1,100 | SealedSep 29, 2026 |
| Nov 2026 | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisNCT06284954 · Empasiprubart IV, Placebo IV | argenx | Other | Phase 2 | 3 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 2026 | A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisNCT06736990 · CAL101, Placebo | Calluna Pharma AS | Respiratory | Phase 2 | 150 | SealedSep 29, 2026 |
| Nov 2026 | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 · Retatrutide, Tirzepatide | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 800 | SealedSep 29, 2026 |
| Nov 2026 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabNCT06389136 · Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose | AbbVie | Immunology & inflammation | Phase 3 | 184 | Not forecastNo arm registered as a control |
| Nov 2026 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)NCT05822752 · Budigalimab, Livmoniplimab, Lenvatinib | AbbVie | Oncology | Phase 2 | 130 | SealedSep 29, 2026 |
| Nov 2026 | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)NCT06118333 · BL-B01D1, capecitabine, gemcitabine | Sichuan Baili Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 386 | Not forecastNo arm registered as a control |
| Nov 2026 | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseNCT05202509 · Obicetrapib, Placebo | NewAmsterdam Pharma | Cardiovascular | Phase 3 | 9,541 | SealedSep 29, 2026 |
| Nov 2026 | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaNCT06637501 · Sonrotoclax, Zanubrutinib | BeOne Medicines | Oncology | Phase 2 | 94 | SealedSep 29, 2026 |
| Nov 2026 | A Study Evaluating APG777 in Atopic DermatitisNCT06395948 · APG777, Placebo | Apogee Therapeutics, Inc. | Immunology & inflammation | Phase 2 | 470 | SealedSep 29, 2026 |
| Nov 2026 | A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinNCT07215312 · LY3938577, Degludec | Eli Lilly and Company | Diabetes & obesity | Phase 2 | 100 | SealedSep 29, 2026 |
| Nov 2026 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)NCT07246590 · VP-102, Vehicle | Verrica Pharmaceuticals Inc. | Other | Phase 3 | 302 | SealedSep 29, 2026 |
| Nov 2026 | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)NCT06355531 · FNP-223, Placebo | Ferrer Internacional S.A. | Other | Phase 2 | 241 | SealedSep 29, 2026 |
| Nov 2026 | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightNCT06962280 · Tirzepatide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 465 | SealedSep 29, 2026 |
| Nov 2026 | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightNCT06914895 · Tirzepatide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 905 | SealedSep 29, 2026 |
| Nov 2026 | Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)NCT07003919 · DBV712 250 mcg, Placebo | DBV Technologies | Respiratory | Phase 3 | 480 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 2026 | To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis.NCT07605338 · Colgate SNaP Total 10/10, 1.5 Taurate, Colgate Great Regular Flavor Toothpaste, Flat Trimmed Extra Clean TB | Colgate Palmolive | Other | Phase 3 | 85 | SealedSep 29, 2026 |
| Nov 2026 | A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06448312 · SKB264, Pembrolizumab | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Oncology | Phase 3 | 406 | SealedSep 29, 2026 |
| Nov 2026 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235 · Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside | CG Oncology, Inc. | Oncology | Phase 3 | 367 | SealedSep 29, 2026 |
| Nov 2026 | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811 · Tobevibart, Elebsiran, Bulevirtide | Vir Biotechnology, Inc. | Infectious disease & vaccines | Phase 2 | 100 | Not forecastNo arm registered as a control |
| Nov 2026 | Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 YearsNCT07505888 · experimental vaccine, active comparator vaccine | Sinovac Biotech Co., Ltd | Infectious disease & vaccines | Phase 3 | 660 | SealedSep 29, 2026 |
| Nov 2026 | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441 · IMU-838 tablets, Placebo matching IMU-838 tablets | Immunic AG | Neurology | Phase 3 | 1,121 | SealedSep 29, 2026 |
| Nov 2026 | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerNCT04486378 · RO7198457 intravenous (IV), Observational group (no intervention) | BioNTech SE | Oncology | Phase 2 | 327 | Not forecastNo arm registered as a control |
| Nov 2026 | A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary AldosteronismNCT07470983 · HRS-1780 Tablets, Placebo | Shandong Suncadia Medicine Co., Ltd. | Other | Phase 2 | 61 | SealedSep 29, 2026 |
| Nov 2026 | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETNCT05050942 · CAM2029, Octreotide LAR, Lanreotide ATG | Camurus AB | Oncology | Phase 3 | 332 | SealedSep 29, 2026 |
| Nov 2026 | Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisNCT06847724 · CYB704, Ocrevus-EU, Ocrevus-US | Sandoz | Neurology | Phase 3 | 183 | SealedSep 29, 2026 |
| Nov 2026 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaNCT06843590 · ALKS 2680, Placebo | Alkermes, Inc. | Other | Phase 2 | 126 | SealedSep 29, 2026 |
| Nov 2, 2026 | A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusNCT06015737 · Anifrolumab, Placebo | AstraZeneca | Immunology & inflammation | Phase 3 | 339 | SealedSep 29, 2026 |
| Nov 2, 2026 | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaNCT06190951 · cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo | Regeneron Pharmaceuticals | Oncology | Phase 2 | 151 | SealedSep 29, 2026 |
| Nov 2, 2026 | A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyNCT05115110 · RO7204239, Placebo, Risdiplam | Hoffmann-La Roche | Rare genetic disease | Phase 2/3 | 97 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 3, 2026 | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upNCT05677451 · LOU064 (blinded), placebo | Novartis Pharmaceuticals | Immunology & inflammation | Phase 3 | 100 | SealedSep 29, 2026 |
| Nov 4, 2026 | Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and GingivitisNCT07917507 · 0.412% stannous fluoride toothpaste and flat trimmed toothbrush, 0.76% Na MFP and flat trimmed toothbrush | Colgate Palmolive | Other | Phase 3 | 84 | SealedNov 5, 2026 |
| Nov 4, 2026 | A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential HypertensionNCT06647745 · THP-00101, THP-00102, THP-00103 | THPharm Corp. | Diabetes & obesity | Phase 3 | 222 | SealedSep 29, 2026 |
| Nov 10, 2026 | LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.NCT06351020 · LM-302, Apatinib, Irinotecan | LaNova Medicines Zhejiang Co., Ltd. | Oncology | Phase 3 | 387 | SealedSep 29, 2026 |
| Nov 12, 2026 | A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisNCT05995964 · PF-07275315, PF-07264660, Placebo | Pfizer | Immunology & inflammation | Phase 2 | 507 | Not forecastNo arm registered as a control |
| Nov 13, 2026 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USNCT07431086 · Olatorepatide, Placebo | Regeneron Pharmaceuticals | Diabetes & obesity | Phase 2 | 120 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 14, 2026 | A Study of BGM0504 in Participants With Type 2 DiabetesNCT06716216 · Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SC, Drug: Semaglutide Administered SC | BrightGene Bio-Medical Technology Co., Ltd. | Diabetes & obesity | Phase 3 | 537 | SealedSep 29, 2026 |
| Nov 14, 2026 | A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseNCT06716203 · Drug: 5 mg BGM0504 Administered SC, Drug: : 10 mg BGM0504 Administered SC, Drug: Placebo Administered SC | BrightGene Bio-Medical Technology Co., Ltd. | Diabetes & obesity | Phase 3 | 207 | SealedSep 29, 2026 |
| Nov 15, 2026 | Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular HypertensionNCT06964191 · PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution | PolyActiva Pty Ltd | Ophthalmology | Phase 2 | 75 | SealedSep 29, 2026 |
| Nov 17, 2026 | An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCNCT06894511 · AAA617, ARPI: Abiraterone, ARPI: Enzalutamide | Novartis Pharmaceuticals | Oncology | Phase 2 | 7 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 18, 2026 | Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide PolymorphismsNCT01064466 · ETOPOSIDE - Usual, ETOPOSIDE - Study | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | Oncology | Phase 2/3 | 600 | Not forecastNot a treatment or prevention trial |
| Nov 18, 2026 | Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide PolymorphismsNCT03348670 · Abiraterone - Usual, Abiraterone - Study | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Oncology | Phase 2/3 | 600 | Not forecastNot a treatment or prevention trial |
| Nov 18, 2026 | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeNCT05946941 · Deucravacitinib, Placebo | Bristol-Myers Squibb | Immunology & inflammation | Phase 3 | 774 | SealedSep 29, 2026 |
| Nov 19, 2026 | A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)NCT06402838 · RO7269162, Placebo | Hoffmann-La Roche | Neurology | Phase 2 | 256 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 19, 2026 | A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisNCT07230860 · JNJ-95597528, Placebo | Janssen Research & Development, LLC | Immunology & inflammation | Phase 2 | 189 | SealedSep 29, 2026 |
| Nov 20, 2026 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)NCT04634877 · Pembrolizumab, Carboplatin, Paclitaxel | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 990 | SealedSep 29, 2026 |
| Nov 20, 2026 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT05851443 · povorcitinib, placebo, ICS-LABA | Incyte Corporation | Respiratory | Phase 2 | 247 | SealedSep 29, 2026 |
| Nov 20, 2026 | Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboNCT06577090 · Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc. | Diabetes & obesity | Phase 2 | 136 | SealedSep 29, 2026 |
| Nov 24, 2026 | A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)NCT06616974 · TX000045- Dose A, TX000045- Dose B, Placebo | Tectonic Therapeutic | Cardiovascular | Phase 2 | 191 | SealedSep 29, 2026 |
| Nov 26, 2026 | A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerNCT03981796 · Dostarlimab, Placebo matching dostarlimab, Carboplatin | Tesaro, Inc. | Oncology | Phase 3 | 785 | SealedSep 29, 2026 |
| Nov 28, 2026 | A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's DiseaseNCT06773962 · TB006, Placebo | TrueBinding, Inc. | Neurology | Phase 2 | 62 | SealedSep 29, 2026 |
| Nov 28, 2026 | A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric PopulationNCT07103148 · Yellow fever vaccine (live), Yellow fever vaccine (live), Yellow fever vaccine (live) | Sanofi | Other | Phase 3 | 2,440 | SealedSep 29, 2026 |
| Nov 30, 2026 | A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyNCT06968585 · A166, T-DM1 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Oncology | Phase 3 | 365 | SealedSep 29, 2026 |
| Nov 30, 2026 | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsNCT07656727 · Oral BGE-102, Oral Placebo Matching BGE-102 | BioAge Labs, Inc. | Diabetes & obesity | Phase 2 | 160 | SealedSep 29, 2026 |
| Nov 30, 2026 | Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee PainNCT07226258 · SL1002, Normal Saline | Saol Therapeutics Inc | Immunology & inflammation | Phase 3 | 150 | SealedSep 29, 2026 |
| Nov 30, 2026 | Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsNCT07199569 · Jynneos, MVA-BN (Quail) | Bavarian Nordic | Infectious disease & vaccines | Phase 2 | 970 | Not forecastNot a treatment or prevention trial |
| Nov 30, 2026 | RNS System LGS Feasibility StudyNCT05339126 · RNS System | NeuroPace | Neurology | Phase 2 | 24 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 2026 | Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric InjuryNCT05776277 · Iltamiocel, Placebo | Cook MyoSite | Other | Phase 3 | 200 | SealedSep 29, 2026 |
| Dec 2026 | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With PolyangiitisNCT06046222 · NS-229, Placebo | NS Pharma, Inc. | Immunology & inflammation | Phase 2 | 45 | SealedSep 29, 2026 |
| Dec 2026 | Safety and Efficacy of VDPHL01 in Males With AGANCT06972264 · VDPHL01, Placebo | Veradermics, Inc. | Immunology & inflammation | Phase 3 | 480 | SealedSep 29, 2026 |
| Dec 2026 | Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypeNCT05397639 · Masupirdine 50 mg, Masupirdine 100 mg, Placebo | Suven Life Sciences Limited | Neurology | Phase 3 | 375 | SealedSep 29, 2026 |
| Dec 2026 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) TherapyNCT06994650 · HRS9531, Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Diabetes & obesity | Phase 3 | 144 | SealedSep 29, 2026 |
| Dec 2026 | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineNCT07010471 · 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo | Praxis Precision Medicines | Neurology | Phase 3 | 160 | SealedSep 29, 2026 |
| Dec 2026 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022 · Selinexor (combination therapy), Selinexor (combination therapy), Selinexor (combination therapy) | Karyopharm Therapeutics Inc | Oncology | Phase 2/3 | 501 | SealedSep 29, 2026 |
| Dec 2026 | A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)NCT06382129 · BL-B01D1, Docetaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 698 | Not forecastNo arm registered as a control |
| Dec 2026 | A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.NCT05987358 · TQB3454 tablets, TQB3454 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Oncology | Phase 3 | 165 | SealedSep 29, 2026 |
| Dec 2026 | A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06711900 · SKB264, Pembrolizumab, pemetrexed | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Oncology | Phase 3 | 432 | SealedSep 29, 2026 |
| Dec 2026 | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550 · Tobevibart, Elebsiran, Bulevirtide | Vir Biotechnology, Inc. | Infectious disease & vaccines | Phase 3 | 150 | Not forecastNo arm registered as a control |
| Dec 2026 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NCT02227251 · Selinexor, Selinexor, Selinexor | Karyopharm Therapeutics Inc | Oncology | Phase 2 | 244 | Not forecastNo arm registered as a control |
| Dec 2026 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT06468228 · Lutikizumab, Placebo | AbbVie | Immunology & inflammation | Phase 3 | 1,400 | Not forecastNo arm registered as a control |
| Dec 2026 | Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior UveitisNCT07285070 · Tacrolimus ophthalmic solution | Novaliq GmbH | Ophthalmology | Phase 2 | 20 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 2026 | A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT06707883 · TQC2731 injection, TQC2731 Placebo | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Respiratory | Phase 2 | 258 | SealedSep 29, 2026 |
| Dec 2026 | ZILRETTA in Subjects With Shoulder OsteoarthritisNCT06269705 · ZILRETTA, Placebo | Pacira Pharmaceuticals, Inc | Immunology & inflammation | Phase 3 | 150 | SealedSep 29, 2026 |
| Dec 2026 | Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate HypertensionNCT07297797 · HRS-9563 Injection, sodium chloride injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Cardiovascular | Phase 2 | 238 | Not forecastNo arm registered as a control |
| Dec 2026 | A Clinical Study Evaluating Licaminlimab for Dry Eye DiseaseNCT07548632 · Artificial Tear Run-in, licaminlimab, Vehicle of licaminlimab | Oculis | Ophthalmology | Phase 2/3 | 160 | SealedSep 29, 2026 |
| Dec 2026 | This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate InfluenzaNCT07371650 · TRX-100, Standard of Care (SOC) | Traws Pharma, Inc. | Infectious disease & vaccines | Phase 2 | 105 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 2026 | Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)NCT06912633 · human retinal progenitor cells, Mock injection | jCyte, Inc | Ophthalmology | Phase 2 | 31 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 2026 | A Study of Navenibart in Participants With Hereditary AngioedemaNCT06842823 · navenibart, Placebo | Astria Therapeutics, Inc. | Other | Phase 3 | 157 | SealedSep 29, 2026 |
| Dec 2026 | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabNCT06107413 · ABBV-400, Bevacizumab, Folinic Acid | AbbVie | Oncology | Phase 2 | 280 | Not forecastNo arm registered as a control |
| Dec 2026 | Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)NCT06721871 · Crofelemer Powder for Oral Solution, Placebo Powder for Oral Solution | Napo Pharmaceuticals, Inc. | Other | Phase 2/3 | 6 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 2026 | Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic PainNCT06848348 · Halneuron, Placebo, Halneuron (Open Label Extension) | Dogwood Therapeutics Inc. | Neurology | Phase 2 | 240 | SealedSep 29, 2026 |
| Dec 2026 | Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderNCT07221578 · VQW-765, Placebo | Vanda Pharmaceuticals | Psychiatry | Phase 3 | 500 | SealedSep 29, 2026 |
| Dec 2026 | Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoENCT06596252 · Budesonide | Dr. Falk Pharma GmbH | Other | Phase 3 | 308 | SealedSep 29, 2026 |
| Dec 2026 | Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)NCT07074977 · nemolizumab, Placebo | Galderma R&D | Other | Phase 2 | 50 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 2026 | A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic RhinitisNCT07688772 · SHR-1819 Injection, SHR-1819 Injection Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | Respiratory | Phase 3 | 220 | SealedSep 29, 2026 |
| Dec 2026 | A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)NCT06500026 · BL-B01D1, Topotecan | Sichuan Baili Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 722 | Not forecastNo arm registered as a control |
| Dec 2026 | A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic AgentsNCT07472725 · SHR-3167 Injection, SHR-3167 Injection Placebo | Jiangsu HengRui Medicine Co., Ltd. | Diabetes & obesity | Phase 2 | 102 | Not forecastNo arm registered as a control |
| Dec 2026 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDNCT04704921 · ABBV-RGX-314, ABBV-RGX-314, Ranibizumab (LUCENTIS®) | AbbVie | Ophthalmology | Phase 2/3 | 671 | SealedSep 29, 2026 |
| Dec 2026 | Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancerNCT05780567 · TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen, Placebo capsules, Letrozole, Anastrozole, Tamoxifen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Oncology | Phase 3 | 1,946 | SealedSep 29, 2026 |
| Dec 2026 | A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor NeuropathyNCT06537999 · Claseprubart, Placebo | Dianthus Therapeutics | Neurology | Phase 2 | 46 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 2026 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaNCT05948475 · Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice | TransThera Sciences (Nanjing), Inc. | Oncology | Phase 3 | 200 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 2026 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)NCT05500222 · Resmetirom, Placebo | Madrigal Pharmaceuticals, Inc. | Liver | Phase 3 | 845 | SealedSep 29, 2026 |
| Dec 2026 | A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLCNCT06671379 · SHR-A2009 monotherapy, platinum-based dual-agent chemotherapy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Oncology | Phase 3 | 498 | SealedSep 29, 2026 |
| Dec 2026 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyNCT06132893 · BHV-7000, BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Neurology | Phase 2/3 | 390 | SealedSep 29, 2026 |
| Dec 2026 | MHB018A Treatment in Patients With Active Thyroid Eye DiseaseNCT06989918 · MHB018A, MHB018A placebo | Minghui Pharmaceutical (Hangzhou) Ltd | Ophthalmology | Phase 3 | 108 | SealedSep 29, 2026 |
| Dec 2026 | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVNCT07037277 · Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir | Atea Pharmaceuticals, Inc. | Infectious disease & vaccines | Phase 3 | 880 | SealedSep 29, 2026 |
| Dec 2026 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus ErythematosusNCT07260877 · VENT-03, Placebo | Ventus Therapeutics U.S., Inc. | Immunology & inflammation | Phase 2 | 24 | SealedSep 29, 2026 |
| Dec 2026 | A Study of SHJ002 Sterile Ophthalmic Solution for Myopia ControlNCT06579287 · SHJ002, Atropine | Sunhawk Vision Biotech, Inc. | Ophthalmology | Phase 2 | 140 | SealedSep 29, 2026 |
| Dec 2026 | A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)NCT06577935 · AGA2118, Placebo | Angitia Biopharmaceuticals | Endocrine & bone | Phase 2 | 379 | SealedSep 29, 2026 |
| Dec 2026 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyNCT05477576 · RYZ101, Everolimus, Sunitinib | RayzeBio, Inc. | Oncology | Phase 3 | 343 | SealedSep 29, 2026 |
| Dec 2026 | A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)NCT04344158 · AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Oncology | Phase 3 | 648 | SealedSep 29, 2026 |
| Dec 2026 | Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)NCT04639986 · Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product | Gilead Sciences | Oncology | Phase 3 | 331 | SealedSep 29, 2026 |
| Dec 1, 2026 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)NCT06685757 · Felzartamab, Placebo | Biogen | Kidney | Phase 3 | 132 | SealedSep 29, 2026 |
| Dec 1, 2026 | Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and AdolescentsNCT06838000 · PCV21, 20vPCV | Sanofi Pasteur, a Sanofi Company | Infectious disease & vaccines | Phase 3 | 1,268 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 1, 2026 | Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline DystrophyNCT06699108 · VGR-R01 | Shanghai Vitalgen BioPharma Co., Ltd. | Ophthalmology | Phase 3 | 45 | SealedSep 29, 2026 |
| Dec 1, 2026 | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyNCT03767244 · Apalutamide, Androgen Deprivation Therapy (ADT), Placebo | Janssen Research & Development, LLC | Oncology | Phase 3 | 2,517 | Not forecastNo arm registered as a control |
| Dec 2, 2026 | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataNCT07029711 · Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo | Pfizer | Immunology & inflammation | Phase 3 | 208 | SealedSep 29, 2026 |
| Dec 3, 2026 | A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the BodyNCT06421636 · REGN7999, Placebo | Regeneron Pharmaceuticals | Hematology | Phase 2 | 19 | SealedSep 29, 2026 |
| Dec 3, 2026 | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT06991556 · JSB462, Abiraterone, Enzalutamide | Novartis Pharmaceuticals | Oncology | Phase 2 | 168 | SealedNov 11, 2026 |
| Dec 3, 2026 | A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseNCT06602258 · E2814, Lecanemab, Placebo | Eisai Inc. | Neurology | Phase 2 | 105 | Not forecastNo arm registered as a control |
| Dec 8, 2026 | A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.NCT07228390 · Ritlecitinib, Placebo | Pfizer | Immunology & inflammation | Phase 2 | 128 | SealedSep 29, 2026 |
| Dec 8, 2026 | A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationNCT05757869 · Milvexian, Apixaban, Placebo | Janssen Research & Development, LLC | Cardiovascular | Phase 3 | 20,284 | SealedSep 29, 2026 |
| Dec 10, 2026 | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574 · zongertinib, pembrolizumab, cisplatin | Boehringer Ingelheim | Oncology | Phase 3 | 428 | SealedSep 29, 2026 |
| Dec 10, 2026 | A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.NCT07222917 · Baxdrostat/dapagliflozin, Baxdrostat/Placebo | AstraZeneca | Cardiovascular | Phase 2 | 222 | SealedSep 29, 2026 |
| Dec 12, 2026 | Efficacy and Safety of ZT006 in Overweight and Obese ParticipantsNCT07230132 · ZT006, Placebo of ZT006, ZT006 | Beijing QL Biopharmaceutical Co.,Ltd | Diabetes & obesity | Phase 2 | 184 | SealedSep 29, 2026 |
| Dec 13, 2026 | To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic ArthritisNCT04957550 · SHR0302 tablets、Placebo, SHR0302 tablets、Placebo, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Immunology & inflammation | Phase 3 | 418 | SealedSep 29, 2026 |
| Dec 14, 2026 | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)NCT06430866 · ABP 234, Pembrolizumab | Amgen | Oncology | Phase 3 | 163 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 14, 2026 | A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityNCT07184632 · NNC0662-0419, Placebo | Novo Nordisk A/S | Diabetes & obesity | Phase 2 | 224 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 14, 2026 | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)NCT06122779 · BMS-986435, Placebo | Bristol-Myers Squibb | Cardiovascular | Phase 2 | 227 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 15, 2026 | A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsNCT07435428 · Corabotase, Placebo | Ipsen | Other | Phase 3 | 1,300 | SealedSep 29, 2026 |
| Dec 15, 2026 | A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsNCT07427797 · Corabotase, Placebo | Ipsen | Other | Phase 3 | 309 | SealedSep 29, 2026 |
| Dec 15, 2026 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673 · XL092, Nivolumab, Sunitinib Malate | Exelixis | Oncology | Phase 3 | 317 | SealedSep 29, 2026 |
| Dec 16, 2026 | A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerNCT06747338 · KN026, HB1801, Pertuzumab | Shanghai JMT-Bio Inc. | Oncology | Phase 3 | 520 | SealedSep 29, 2026 |
| Dec 16, 2026 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisNCT05503264 · Satralizumab, Placebo | Hoffmann-La Roche | Oncology | Phase 3 | 122 | SealedSep 29, 2026 |
| Dec 17, 2026 | A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisNCT06975722 · SAR442970, Placebo | Sanofi | Immunology & inflammation | Phase 2 | 105 | SealedSep 29, 2026 |
| Dec 17, 2026 | A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyNCT07363720 · TAK-861, Placebo | Takeda | Other | Phase 3 | 98 | SealedSep 29, 2026 |
| Dec 17, 2026 | Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseNCT06268886 · BMS-986446, Placebo | Bristol-Myers Squibb | Neurology | Phase 2 | 310 | SealedSep 29, 2026 |
| Dec 18, 2026 | Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)NCT07246889 · AHB-137, Placebo, NA therapy | Ausper Biopharma Co., Ltd. | Infectious disease & vaccines | Phase 3 | 577 | SealedSep 29, 2026 |
| Dec 18, 2026 | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide PolymorphismsNCT07145333 · Topotecan - usual, Topotecan - study | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | Other | Phase 2/3 | 600 | Not forecastNot a treatment or prevention trial |
| Dec 18, 2026 | Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide PolymorphismsNCT06062810 · Raloxifene - Usual, Raloxifene - Study | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Oncology | Phase 2/3 | 600 | Not forecastNot a treatment or prevention trial |
| Dec 22, 2026 | Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationNCT06856577 · Ixo-vec, Aflibercept | Adverum Biotechnologies, Inc. | Ophthalmology | Phase 3 | 311 | SealedSep 29, 2026 |
| Dec 22, 2026 | A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseNCT06544616 · JNJ-64042056, Placebo | Janssen Pharmaceutica N.V., Belgium | Neurology | Phase 2 | 55 | SealedSep 29, 2026 |
| Dec 22, 2026 | A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyNCT06769048 · Placebo-matching BI 1584862, BI 1584862 | Boehringer Ingelheim | Ophthalmology | Phase 2 | 150 | SealedSep 29, 2026 |
| Dec 23, 2026 | A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaNCT05692180 · Benralizumab, Placebo | AstraZeneca | Respiratory | Phase 3 | 94 | SealedSep 29, 2026 |
| Dec 23, 2026 | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCNCT05849298 · AAA617, AAA517, Piflufolastat F 18 | Novartis Pharmaceuticals | Oncology | Phase 2 | 49 | Not forecastNo arm registered as a control |
| Dec 23, 2026 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06402331 · FPI-2265 | Fusion Pharmaceuticals Inc. | Oncology | Phase 2 | 110 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 26, 2026 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryNCT04498117 · Oregovomab, Paclitaxel, Carboplatin | CanariaBio Inc. | Oncology | Phase 3 | 615 | SealedSep 29, 2026 |
| Dec 26, 2026 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaNCT06212999 · Povorcitinib | Incyte Corporation | Immunology & inflammation | Phase 3 | 617 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 28, 2026 | Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSILNCT05555862 · Artesunate, Placebo | Frantz Viral Therapeutics, LLC | Oncology | Phase 2 | 17 | SealedSep 29, 2026 |
| Dec 29, 2026 | A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaNCT07477704 · Alirocumab | Regeneron Pharmaceuticals | Cardiovascular | Phase 2 | 438 | Not forecastNo arm registered as a control |
| Dec 30, 2026 | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderNCT04658862 · Cetrelimab, TAR-200, Cisplatin | Janssen Research & Development, LLC | Oncology | Phase 3 | 518 | SealedSep 29, 2026 |
| Dec 30, 2026 | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaNCT06206733 · ASKB589, Oxaliplatin, Capecitabine | AskGene Pharma, Inc. | Oncology | Phase 3 | 780 | SealedSep 29, 2026 |
| Dec 30, 2026 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerNCT05909397 · Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole | Pfizer | Oncology | Phase 3 | 59 | SealedSep 29, 2026 |
| Dec 30, 2026 | SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerNCT06465563 · SHR-8068, Adebrelimab, Cisplatin | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Oncology | Phase 2 | 93 | Not forecastNo arm registered as a control |
| Dec 30, 2026 | A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)NCT06238843 · Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）, IBI343 | Innovent Biologics (Suzhou) Co. Ltd. | Oncology | Phase 3 | 464 | SealedSep 29, 2026 |
| Dec 30, 2026 | Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)NCT05563844 · PM 8.4 mg/m^2, PM 11.2 mg/m^2 | Chengdu Zenitar Biomedical Technology Co., Ltd | Oncology | Phase 2 | 74 | Not forecastNo arm registered as a control |
| Dec 30, 2026 | SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsNCT05631262 · SKB264, Docetaxel | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Oncology | Phase 2 | 321 | SealedSep 29, 2026 |
| Dec 30, 2026 | Iptacopan in Patients With ANCA Associated VasculitisNCT06388941 · Iptacopan, Placebo, Rituximab | Novartis Pharmaceuticals | Immunology & inflammation | Phase 2 | 84 | SealedSep 29, 2026 |
| Dec 30, 2026 | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisNCT06799247 · Decartes-08, Placebo Drug | Cartesian Therapeutics | Immunology & inflammation | Phase 3 | 128 | SealedSep 29, 2026 |
| Dec 30, 2026 | Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in AdultsNCT06547151 · AMOR-1, Crystalline Calcium Carbonate | Amorphical Ltd. | Endocrine & bone | Phase 2 | 62 | SealedSep 29, 2026 |
| Dec 30, 2026 | Phase II Study of Hemay005 in Patients With Active Ulcerative ColitisNCT05486104 · Hemay005 tablets, Hemay005 placebo tablets | Ganzhou Hemay Pharmaceutical Co., Ltd | Immunology & inflammation | Phase 2 | 92 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerNCT05645692 · Atezolizumab, Tobemstomig, Tiragolumab | Hoffmann-La Roche | Oncology | Phase 2 | 204 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 31, 2026 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerNCT04691804 · Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Oncology | Phase 3 | 496 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyNCT06797297 · IBI363, Pembrolizumab | Innovent Biologics (Suzhou) Co. Ltd. | Oncology | Phase 2 | 203 | SealedSep 29, 2026 |
| Dec 31, 2026 | Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial CystitisNCT06284265 · Raphamin, Placebo | Materia Medica Holding | Other | Phase 3 | 415 | SealedSep 29, 2026 |
| Dec 31, 2026 | Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 YearsNCT06281119 · Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen | Serum Institute of India Pvt. Ltd. | Infectious disease & vaccines | Phase 3 | 450 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseNCT03887455 · Lecanemab IV, Placebo, Lecanemab SC | Eisai Inc. | Neurology | Phase 3 | 1,906 | SealedOct 7, 2026 |
| Dec 31, 2026 | Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)NCT07162883 · QL2107, Keytruda® | Qilu Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 146 | SealedSep 29, 2026 |
| Dec 31, 2026 | SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerNCT04977024 · COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 | GeoVax, Inc. | Oncology | Phase 2 | 63 | Not forecastNo arm registered as a control |
| Dec 31, 2026 | Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)NCT06931405 · BLU-808, Placebo | Blueprint Medicines Corporation | Immunology & inflammation | Phase 2 | 105 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 31, 2026 | A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVTNCT05198323 · LT3001 Drug Product, Placebo | Lumosa Therapeutics Co., Ltd. | Cardiovascular | Phase 2 | 66 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）NCT06884293 · IBI362, semaglutide | Innovent Biologics (Suzhou) Co. Ltd. | Diabetes & obesity | Phase 3 | 479 | SealedSep 29, 2026 |
| Dec 31, 2026 | MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784 · MN-001, MN-001 placebo | MediciNova | Diabetes & obesity | Phase 2 | 40 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）NCT06908876 · IBI302, IBI302, Faricimab | Innovent Biologics Technology Limited (Shanghai R&D Center) | Ophthalmology | Phase 2 | 150 | SealedSep 29, 2026 |
| Dec 31, 2026 | Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic PatientsNCT04318041 · Artrodar, Placebos | TRB Chemedica | Immunology & inflammation | Phase 3 | 128 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With PterygiumNCT05456425 · CBT-001, Vehicle | Cloudbreak Therapeutics, LLC | Other | Phase 3 | 660 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)NCT07391241 · Pudafensine | Initiator Pharma | Other | Phase 2 | 24 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)NCT06660394 · LP352, Placebo | Longboard Pharmaceuticals | Other | Phase 3 | 108 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior UveitisNCT07136805 · VVN461 Ophthalmic Solution 1.0%, 1.0% prednisolone acetate | VivaVision Biotech, Inc | Ophthalmology | Phase 3 | 154 | SealedSep 29, 2026 |
| Dec 31, 2026 | Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's DiseaseNCT05910528 · Afimkibart | Hoffmann-La Roche | Immunology & inflammation | Phase 2 | 21 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Dec 31, 2026 | Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep ApneaNCT06776432 · Sivopixant, Placebo, Acetazolamide | Shionogi | Other | Phase 2 | 60 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusNCT05672576 · Cenerimod, Placebo | Viatris Innovation GmbH | Immunology & inflammation | Phase 3 | 451 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne VulgarisNCT07186413 · Trifarotene, Vehicle Cream | Galderma R&D | Other | Phase 3 | 561 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneNCT05424835 · SHR-A1811, Pyrotinib in combination with Capecitabine., SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | Oncology | Phase 3 | 381 | SealedSep 29, 2026 |
| Dec 31, 2026 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)NCT06531824 · BI 690517, Placebo matching BI 690517, Empagliflozin | Boehringer Ingelheim | Cardiovascular | Phase 3 | 8,371 | SealedSep 29, 2026 |
| Dec 31, 2026 | A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsNCT06052267 · TEV-56248, Albuterol sulfate | Teva Branded Pharmaceutical Products R&D LLC | Respiratory | Phase 3 | 2,769 | SealedSep 29, 2026 |
| Dec 31, 2026 | Efficacy of SALI-10 Oral Probiotics in Experimental GingivitisNCT07256743 · SALI-10 lozenge, Placebo lozenge | Ostia Sciences | Other | Phase 2 | 60 | SealedSep 29, 2026 |
| Jan 2027 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)NCT06109272 · Livmoniplimab, Budigalimab, Durvalumab | AbbVie | Oncology | Phase 2/3 | 89 | SealedSep 29, 2026 |
| Jan 2027 | Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and AboveNCT07481604 · Shingrix, CVI-VZV-001 | Aribio Lab Co., Ltd. | Other | Phase 2 | 135 | SealedSep 29, 2026 |
| Jan 2027 | Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisNCT06029972 · Tilpisertib Fosmecarbil, Placebo | Gilead Sciences | Immunology & inflammation | Phase 2 | 176 | SealedSep 29, 2026 |
| Jan 2027 | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891 · Sotagliflozin, Placebo | Lexicon Pharmaceuticals | Cardiovascular | Phase 3 | 500 | SealedSep 29, 2026 |
| Jan 2027 | A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaNCT05751928 · BCD-217, anti-PD1, Excision of the primary lesion | Biocad | Oncology | Phase 3 | 411 | SealedSep 29, 2026 |
| Jan 2027 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)NCT05540860 · Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3 | Edgewise Therapeutics, Inc. | Rare genetic disease | Phase 2 | 76 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jan 2027 | Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisNCT06701331 · Placebo, Upadacitinib | AbbVie | Immunology & inflammation | Phase 3 | 99 | SealedSep 29, 2026 |
| Jan 2027 | A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With GlioblastomaNCT04485949 · IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy | Imvax | Oncology | Phase 2 | 99 | SealedSep 29, 2026 |
| Jan 2027 | Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes MellitusNCT07205900 · HM15275, Placebo of HM15275 | Hanmi Pharmaceutical Company Limited | Diabetes & obesity | Phase 2 | 267 | SealedSep 29, 2026 |
| Jan 2027 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisNCT05050136 · Volixibat, Placebo | Mirum Pharmaceuticals, Inc. | Liver | Phase 2 | 333 | SealedSep 29, 2026 |
| Jan 2027 | Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresNCT07505004 · 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks | Praxis Precision Medicines | Neurology | Phase 3 | 300 | SealedSep 29, 2026 |
| Jan 2027 | A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyNCT06384261 · Cusatuzumab, Venetoclax, Azacitidine | OncoVerity, Inc. | Oncology | Phase 2 | 140 | SealedSep 29, 2026 |
| Jan 2027 | A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerNCT06561607 · TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Oncology | Phase 3 | 542 | SealedSep 29, 2026 |
| Jan 1, 2027 | Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSNCT04957485 · Tecovirimat, Smallpox and Mpox Vaccine, Placebo | SIGA Technologies | Other | Phase 2 | 100 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jan 4, 2027 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseNCT06641089 · Sonelokimab, Placebo, Risankizumab | MoonLake Immunotherapeutics AG | Immunology & inflammation | Phase 3 | 600 | SealedSep 29, 2026 |
| Jan 4, 2027 | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHNCT07000136 · AZD0780, Placebo | AstraZeneca | Cardiovascular | Phase 3 | 473 | SealedSep 29, 2026 |
| Jan 6, 2027 | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)NCT05925803 · Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label) | AstraZeneca | Immunology & inflammation | Phase 3 | 314 | SealedSep 29, 2026 |
| Jan 8, 2027 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNCT06495918 · OTX-TKI, Aflibercept, Aflibercept | Ocular Therapeutix, Inc. | Ophthalmology | Phase 3 | 825 | SealedSep 29, 2026 |
| Jan 8, 2027 | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840 · Durvalumab, Oleclumab, Monalizumab | AstraZeneca | Oncology | Phase 3 | 1,051 | SealedSep 29, 2026 |
| Jan 8, 2027 | A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis BronchiectasisNCT06981091 · XH-S004 20 mg, XH-S004 40 mg, Placebo | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Respiratory | Phase 2 | 234 | SealedSep 29, 2026 |
| Jan 11, 2027 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814 · Dato-DXd, Osimertinib, Pemetrexed | AstraZeneca | Oncology | Phase 3 | 768 | Not forecastNo arm registered as a control |
| Jan 11, 2027 | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventNCT07000123 · AZD0780, Placebo | AstraZeneca | Cardiovascular | Phase 3 | 3,103 | SealedSep 29, 2026 |
| Jan 11, 2027 | A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMENCT06957080 · Remigromig, Ranibizumab | EyeBiotech Ltd. | Ophthalmology | Phase 2/3 | 1,054 | SealedSep 29, 2026 |
| Jan 12, 2027 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)NCT05609968 · Sacituzumab Govitecan, Pembrolizumab | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 614 | Not forecastNo arm registered as a control |
| Jan 13, 2027 | Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet TherapyNCT05952206 · Angiolite: Sirolimus-eluting stent, Xience: Everolimus-eluting stent, 1-month DAPT | iVascular S.L.U. | Cardiovascular | Phase 3 | 2,312 | SealedSep 29, 2026 |
| Jan 15, 2027 | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryNCT05608291 · Fianlimab, Cemiplimab, Pembrolizumab | Regeneron Pharmaceuticals | Oncology | Phase 3 | 1,564 | SealedSep 29, 2026 |
| Jan 15, 2027 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332 · IDE196, Crizotinib, Pembrolizumab | IDEAYA Biosciences | Oncology | Phase 2/3 | 420 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jan 15, 2027 | Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)NCT04199689 · 9vHPV Vaccine, Placebo (Saline for Injection) | Merck Sharp & Dohme LLC | Infectious disease & vaccines | Phase 3 | 6,033 | SealedSep 29, 2026 |
| Jan 18, 2027 | Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.NCT05035212 · RSVpreF, Placebo | Pfizer | Infectious disease & vaccines | Phase 3 | 38,861 | SealedSep 29, 2026 |
| Jan 19, 2027 | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)NCT05170204 · Alectinib, Entrectinib, Durvalumab | Hoffmann-La Roche | Oncology | Phase 3 | 68 | SealedNov 3, 2026 |
| Jan 21, 2027 | Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · Maridebart Cafraglutide, Placebo | Amgen | Diabetes & obesity | Phase 3 | 3,853 | SealedSep 29, 2026 |
| Jan 21, 2027 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 · Maridebart cafraglutide, Placebo | Amgen | Diabetes & obesity | Phase 3 | 1,105 | SealedSep 29, 2026 |
| Jan 25, 2027 | A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199 · Insulin icodec, Insulin glargine, Insulin aspart | Novo Nordisk A/S | Diabetes & obesity | Phase 3 | 877 | SealedSep 29, 2026 |
| Jan 26, 2027 | A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaNCT05757102 · FF/UMEC/VI, ELLIPTA, FF/VI | GlaxoSmithKline | Respiratory | Phase 3 | 138 | SealedSep 29, 2026 |
| Jan 28, 2027 | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsNCT07496450 · mRNA-1018-H5, Placebo | ModernaTX, Inc. | Infectious disease & vaccines | Phase 3 | 4,050 | SealedSep 29, 2026 |
| Jan 28, 2027 | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.NCT05038735 · Alpelisib, Fulvestrant, Alpelisib-matching placebo | Novartis Pharmaceuticals | Oncology | Phase 3 | 210 | SealedSep 29, 2026 |
| Jan 29, 2027 | Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of AgeNCT07207408 · rF1V-1018, rF1V-1018, rF1V-1018 | Dynavax Technologies Corporation | Infectious disease & vaccines | Phase 2 | 148 | Not forecastNo arm registered as a control |
| Jan 29, 2027 | Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerNCT04544189 · Alpelisib, Fulvestrant, Placebo | Novartis Pharmaceuticals | Oncology | Phase 2 | 69 | SealedSep 29, 2026 |
| Jan 29, 2027 | ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackNCT06118281 · Ziltivekimab, Placebo | Novo Nordisk A/S | Cardiovascular | Phase 3 | 10,000 | Not forecastNo arm registered as a control |
| Jan 29, 2027 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2NCT05911295 · disitamab vedotin, pembrolizumab, gemcitabine | Seagen, a wholly owned subsidiary of Pfizer | Oncology | Phase 3 | 412 | SealedSep 29, 2026 |
| Jan 30, 2027 | A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisNCT06589986 · Afimkibart, Placebo | Hoffmann-La Roche | Immunology & inflammation | Phase 3 | 400 | SealedSep 29, 2026 |
| Jan 31, 2027 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)NCT04241185 · Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes) | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 520 | SealedSep 29, 2026 |
| Feb 2027 | A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigraineNCT06602479 · MEDI0618, Placebo | AbbVie | Neurology | Phase 2 | 309 | SealedSep 29, 2026 |
| Feb 2027 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel | Gilead Sciences | Oncology | Phase 3 | 443 | SealedSep 29, 2026 |
| Feb 2027 | A Phase IIb Study of 610 in Participants With Severe Eosinophilic AsthmaNCT06680947 · 610, 610, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Respiratory | Phase 2 | 225 | SealedSep 29, 2026 |
| Feb 2027 | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionNCT06365853 · Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops | AbbVie | Oncology | Phase 2 | 108 | Not forecastNo arm registered as a control |
| Feb 2027 | A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV VaccineNCT06899802 · MVA-BN-WEV, Placebo | Bavarian Nordic | Infectious disease & vaccines | Phase 2 | 411 | SealedSep 29, 2026 |
| Feb 2027 | A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus InfectionNCT07245953 · HT-101, HT-102, HT-101 placebo | Suzhou HepaThera Biotech Co., Ltd. | Infectious disease & vaccines | Phase 2 | 60 | Not forecastNo arm registered as a control |
| Feb 2027 | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyNCT06413706 · Abemaciclib, Temozolomide | Eli Lilly and Company | Oncology | Phase 2 | 45 | SealedSep 29, 2026 |
| Feb 2027 | A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung CancerNCT06939595 · CT-P51, EU-approved Keytruda | Celltrion | Oncology | Phase 3 | 225 | SealedSep 29, 2026 |
| Feb 2027 | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related CataractNCT07395986 · 0.4% ZOC2017217, Control | Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. | Other | Phase 2 | 8 | SealedSep 29, 2026 |
| Feb 2027 | A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or ObesityNCT07724340 · AT673 low dose, AT673 high dose, Placebo | Antag Therapeutics | Diabetes & obesity | Phase 2 | 150 | SealedSep 29, 2026 |
| Feb 2, 2027 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaNCT04417621 · LXH254, LTT462, Trametinib | Novartis Pharmaceuticals | Oncology | Phase 2 | 134 | Not forecastNo arm registered as a control |
| Feb 2, 2027 | An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.NCT05217628 · Basimglurant, Placebo | Noema Pharma AG | Pain | Phase 2/3 | 166 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Feb 3, 2027 | Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate VaccineNCT07743008 · Haemophilus influenzae serotype a vaccine candidate, Saline (as a placebo) | InventVacc Biologicals Inc. | Diabetes & obesity | Phase 2 | 47 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Feb 4, 2027 | Nipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969 · Nipocalimab, Placebo, Standard of care treatment | Janssen Research & Development, LLC | Immunology & inflammation | Phase 3 | 655 | SealedNov 13, 2026 |
| Feb 4, 2027 | A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)NCT04657289 · Ranibizumab, Port Delivery System with Ranibizumab | Hoffmann-La Roche | Ophthalmology | Phase 3 | 451 | SealedSep 29, 2026 |
| Feb 5, 2027 | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)NCT06946797 · Nivolumab, Ipilimumab, Carboplatin | Bristol-Myers Squibb | Oncology | Phase 2 | 76 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Feb 5, 2027 | A Study of Zasocitinib in Adults With Hidradenitis SuppurativaNCT07244263 · Zasocitinib (Dose A), Placebo | Takeda | Immunology & inflammation | Phase 2 | 91 | SealedNov 5, 2026 |
| Feb 9, 2027 | Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric CancerNCT05771584 · AST-301, rhuGM-CSF | Aston Sci. Inc. | Oncology | Phase 2 | 24 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Feb 10, 2027 | A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisNCT06807424 · Icotrokinra, Placebo | Janssen Research & Development, LLC | Immunology & inflammation | Phase 3 | 813 | SealedSep 29, 2026 |
| Feb 10, 2027 | A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisNCT06260163 · Guselkumab Subcutaneous, Guselkumab Intravenous | Janssen Research & Development, LLC | Immunology & inflammation | Phase 3 | 112 | Not forecastNo arm registered as a control |
| Feb 12, 2027 | A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200 · Sub-Retinal Administration of OCU400-301 | Ocugen | Ophthalmology | Phase 3 | 140 | SealedSep 29, 2026 |
| Feb 13, 2027 | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.NCT04224493 · Tazemetostat, Tazemetostat, Placebo oral tablet | Epizyme, Inc. | Oncology | Phase 3 | 599 | SealedSep 29, 2026 |
| Feb 15, 2027 | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisNCT06592794 · mRNA-1403, Placebo | ModernaTX, Inc. | Other | Phase 3 | 37,864 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Feb 15, 2027 | A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)NCT07017777 · PCV13i, Prevnar 13 | CanSino Biologics Inc. | Infectious disease & vaccines | Phase 3 | 600 | SealedSep 29, 2026 |
| Feb 15, 2027 | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLNCT02972840 · Acalabrutinib, Bendamustine, Rituximab | Acerta Pharma BV | Oncology | Phase 3 | 635 | SealedSep 29, 2026 |
| Feb 16, 2027 | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)NCT06140836 · Repotrectinib, Crizotinib | Bristol-Myers Squibb | Oncology | Phase 3 | 190 | SealedSep 29, 2026 |
| Feb 17, 2027 | Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)NCT07486960 · Tulisokibart, Placebo | Merck Sharp & Dohme LLC | Immunology & inflammation | Phase 2 | 140 | SealedSep 29, 2026 |
| Feb 17, 2027 | An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal PolypsNCT07424144 · Itepekimab (SAR440340), Placebo | Sanofi | Respiratory | Phase 3 | 59 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Feb 18, 2027 | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)NCT06087835 · Zibotentan/Dapagliflozin, Dapagliflozin | AstraZeneca | Kidney | Phase 3 | 1,835 | SealedSep 29, 2026 |
| Feb 22, 2027 | A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesNCT06868212 · Remibrutinib, Remibrutinib matching placebo, Dupilumab | Novartis Pharmaceuticals | Immunology & inflammation | Phase 3 | 409 | SealedSep 29, 2026 |
| Feb 22, 2027 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)NCT04529772 · acalabrutinib, placebo, Prednisone | Acerta Pharma BV | Oncology | Phase 3 | 611 | SealedSep 29, 2026 |
| Feb 23, 2027 | Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisNCT05138133 · Anifrolumab, Placebo | AstraZeneca | Kidney | Phase 3 | 363 | SealedSep 29, 2026 |
| Feb 26, 2027 | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationNCT04208178 · Alpelisib, Alpelisib matching Placebo, Trastuzumab | Novartis Pharmaceuticals | Oncology | Phase 3 | 19 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Feb 27, 2027 | A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)NCT07073417 · XW003 injection, semaglutide injection | Hangzhou Sciwind Biosciences Co., Ltd. | Diabetes & obesity | Phase 2 | 163 | SealedSep 29, 2026 |
| Feb 28, 2027 | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830 · ADI-PEG 20, Temozolomide, Placebo | Polaris Group | Oncology | Phase 2 | 100 | SealedSep 29, 2026 |
| Feb 28, 2027 | A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).NCT06551324 · PF-06821497, Docetaxel, Enzalutamide | Pfizer | Oncology | Phase 3 | 609 | SealedSep 29, 2026 |
| Feb 28, 2027 | A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMDNCT05972473 · Aflibercept Ophthalmic, IBI302 | Innovent Biologics (Suzhou) Co. Ltd. | Ophthalmology | Phase 3 | 600 | SealedSep 29, 2026 |
| Feb 28, 2027 | A Study Evaluating BFB759 in Moderate to Severe Atopic DermatitisNCT07105488 · BFB759, Placebo | Bluefin Biomedicine, Inc. | Immunology & inflammation | Phase 2 | 225 | SealedSep 29, 2026 |
| Mar 2027 | A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentNCT06668805 · Vosoritide Injection | BioMarin Pharmaceutical | Endocrine & bone | Phase 2 | 30 | Not forecastNo arm registered as a control |
| Mar 2027 | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeNCT07365826 · 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo | Vaxcyte, Inc. | Infectious disease & vaccines | Phase 3 | 1,390 | Not forecastNo arm registered as a control |
| Mar 2027 | RBD5044 in Chinese Participants With HypertriglyceridemiaNCT07587788 · RBD5044, Placebo | Ribotek Biopharmaceuticals (Shandong) Co., Ltd | Diabetes & obesity | Phase 2 | 40 | Not forecastNo arm registered as a control |
| Mar 2027 | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationNCT07425392 · 31-valent pneumococcal conjugate vaccine, PCV20 | Vaxcyte, Inc. | Infectious disease & vaccines | Phase 3 | 752 | SealedSep 29, 2026 |
| Mar 2027 | A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559 · Macupatide, Eloralintide, Macupatide Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 2 | 200 | SealedSep 29, 2026 |
| Mar 2027 | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerNCT05141721 · GRT-C901, GRT-R902, Atezolizumab | Seattle Project Corporation | Oncology | Phase 2/3 | 700 | SealedSep 29, 2026 |
| Mar 2027 | Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)NCT06602193 · BIIB122 225 mg, BIIB122-Matching Placebo | Denali Therapeutics Inc. | Neurology | Phase 2 | 50 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Mar 2027 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)NCT06456580 · Telitacicept, Placebo | Vor Biopharma | Immunology & inflammation | Phase 3 | 191 | SealedSep 29, 2026 |
| Mar 2027 | A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With ObesityNCT07285902 · HRS9531 injection, Semaglutide Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Diabetes & obesity | Phase 3 | 572 | SealedSep 29, 2026 |
| Mar 2027 | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01NCT06727565 · Domvanalimab, Zimberelimab, Paclitaxel | Gilead Sciences | Oncology | Phase 2 | 39 | Not forecastNo arm registered as a control |
| Mar 2027 | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigraineNCT07018713 · Xeomin, Placebo | Merz Therapeutics GmbH | Neurology | Phase 3 | 808 | SealedSep 29, 2026 |
| Mar 2027 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusNCT05843643 · Upadacitinib, Placebo | AbbVie | Immunology & inflammation | Phase 3 | 1,014 | SealedSep 29, 2026 |
| Mar 2027 | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)NCT06632951 · Livmoniplimab, Budigalimab, Docetaxel | AbbVie | Oncology | Phase 2 | 150 | Not forecastNo arm registered as a control |
| Mar 2027 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsNCT07502495 · icovamenib 100mg, Placebo | Biomea Fusion Inc. | Diabetes & obesity | Phase 2 | 64 | SealedSep 29, 2026 |
| Mar 2027 | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaNCT06929624 · SHR-A1912 Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Oncology | Phase 3 | 282 | SealedSep 29, 2026 |
| Mar 2027 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.NCT06063967 · Risankizumab SC, Placebo for risankizumab | AbbVie | Immunology & inflammation | Phase 3 | 289 | SealedSep 29, 2026 |
| Mar 2027 | Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)NCT05186974 · Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin | Gilead Sciences | Oncology | Phase 2 | 193 | Not forecastNo arm registered as a control |
| Mar 2027 | Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal PolypsNCT07107256 · TQC2731 injection, Placebo of TQC2731 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Respiratory | Phase 3 | 246 | SealedSep 29, 2026 |
| Mar 2027 | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)NCT06963710 · ALG-000184, TDF | Aligos Therapeutics | Infectious disease & vaccines | Phase 2 | 200 | SealedSep 29, 2026 |
| Mar 2027 | Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyNCT06100887 · Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3 | Edgewise Therapeutics, Inc. | Rare genetic disease | Phase 2 | 43 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Mar 2027 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)NCT04951219 · Resmetirom | Madrigal Pharmaceuticals, Inc. | Liver | Phase 3 | 810 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Mar 2027 | A Study of SHR-1918 In Participants With HypertriglyceridemiaNCT07349615 · SHR-1918/ SHR-1918 placebo, SHR-1918/ SHR-1918 placebo | Beijing Suncadia Pharmaceuticals Co., Ltd | Diabetes & obesity | Phase 3 | 367 | Not forecastNo arm registered as a control |
| Mar 2027 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeNCT06872125 · zorevunersen, Sham Comparator | Stoke Therapeutics, Inc | Other | Phase 3 | 170 | SealedSep 29, 2026 |
| Mar 2027 | A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic SclerosisNCT06655155 · Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Immunology & inflammation | Phase 2 | 87 | SealedSep 29, 2026 |
| Mar 2027 | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic MigraineNCT07018700 · Xeomin, Placebo | Merz Therapeutics GmbH | Neurology | Phase 3 | 997 | SealedSep 29, 2026 |
| Mar 1, 2027 | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 · CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Novo Nordisk A/S | Diabetes & obesity | Phase 3 | 609 | SealedSep 29, 2026 |
| Mar 1, 2027 | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASNCT02531516 · Apalutamide, Bicalutamide, Bicalutamide Placebo | Aragon Pharmaceuticals, Inc. | Oncology | Phase 3 | 1,503 | SealedSep 29, 2026 |
| Mar 1, 2027 | Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)NCT05270525 · Ensifentrine, Placebo, LABA/LAMA | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Respiratory | Phase 2 | 70 | Not forecastNo arm registered as a control |
| Mar 4, 2027 | A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsNCT06524414 · PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15) | Pfizer | Infectious disease & vaccines | Phase 2 | 605 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Mar 6, 2027 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.NCT05683457 · mRNA-1647, Placebo | ModernaTX, Inc. | Infectious disease & vaccines | Phase 2 | 84 | SealedSep 29, 2026 |
| Mar 8, 2027 | A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple MyelomaNCT06952478 · CT-P44(Daratumumab), Darzalex Faspro(Daratumumab) | Celltrion | Oncology | Phase 3 | 473 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Mar 9, 2027 | A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque PsoriasisNCT06506916 · bimekizumab | UCB Biopharma SRL | Immunology & inflammation | Phase 3 | 89 | SealedSep 29, 2026 |
| Mar 10, 2027 | Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy AdolescentsNCT05087056 · MenABCWY vaccine, Placebo | GlaxoSmithKline | Other | Phase 2 | 305 | Not forecastNo arm registered as a control |
| Mar 11, 2027 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerNCT03873402 · Nivolumab, Ipilimumab, Ipilimumab placebo | Bristol-Myers Squibb | Oncology | Phase 3 | 437 | Not forecastNo arm registered as a control |
| Mar 11, 2027 | A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard TreatmentNCT07036523 · BI 765423, Placebo | Boehringer Ingelheim | Respiratory | Phase 2 | 81 | SealedSep 29, 2026 |
| Mar 13, 2027 | A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sNCT06928142 · Sibeprenlimab, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Immunology & inflammation | Phase 2 | 83 | SealedSep 29, 2026 |
| Mar 14, 2027 | A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseaseNCT07211776 · ZL-1109 (VRDN-003), Placebo | Zai Lab (Shanghai) Co., Ltd. | Ophthalmology | Phase 3 | 108 | SealedSep 29, 2026 |
| Mar 16, 2027 | Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food AllergyNCT07220811 · RPT904, RPT904, Placebo | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | Respiratory | Phase 2 | 110 | SealedSep 30, 2026 |
| Mar 17, 2027 | A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT06789289 · TQC2938 injection, TQC2938 injection Placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Respiratory | Phase 2 | 256 | SealedSep 29, 2026 |
| Mar 22, 2027 | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)NCT04976634 · Pembrolizumab, Belzutifan, Lenvatinib | Merck Sharp & Dohme LLC | Oncology | Phase 2 | 730 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Mar 24, 2027 | IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian CancerNCT06014528 · IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin | InxMed (Shanghai) Co., Ltd. | Oncology | Phase 2 | 168 | SealedSep 29, 2026 |
| Mar 25, 2027 | 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the KneeNCT06865079 · TPX-100 200mg, Once weekly for 4 weeks, PBS | OrthoTrophix, Inc | Immunology & inflammation | Phase 2 | 270 | SealedSep 29, 2026 |
| Mar 25, 2027 | A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's DiseaseNCT05347095 · Guselkumab, Placebo | Janssen-Cilag Ltd. | Immunology & inflammation | Phase 3 | 288 | Not forecastNo arm registered as a control |
| Mar 26, 2027 | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)NCT05639114 · Ianalumab, Placebo | Novartis Pharmaceuticals | Immunology & inflammation | Phase 3 | 436 | SealedSep 29, 2026 |
| Mar 26, 2027 | A Study of Zasocitinib in Adults With Nonsegmental VitiligoNCT07108283 · Zasocitinib, Placebo | Takeda | Immunology & inflammation | Phase 2 | 207 | Not forecastNo arm registered as a control |
| Mar 28, 2027 | Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)NCT06524947 · quadrivalent recombinant norovirus vaccine (Pichia pastoris), quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Infectious disease & vaccines | Phase 3 | 6,600 | SealedSep 29, 2026 |
| Mar 29, 2027 | A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)NCT07133633 · Tulisokibart, Placebo | Merck Sharp & Dohme LLC | Immunology & inflammation | Phase 2 | 315 | SealedSep 29, 2026 |
| Mar 31, 2027 | A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoNCT06163326 · Ritlecitinib, Ritlecitinib 100 mg, Placebo | Pfizer | Immunology & inflammation | Phase 3 | 394 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Mar 31, 2027 | Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar DegenerationNCT07040137 · KPS-0373, Placebo | Kissei Pharmaceutical Co., Ltd. | Other | Phase 3 | 142 | SealedSep 29, 2026 |
| Mar 31, 2027 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyNCT04873362 · Atezolizumab, Trastuzumab Emtansine, Placebo | Hoffmann-La Roche | Oncology | Phase 3 | 1,188 | SealedSep 29, 2026 |
| Mar 31, 2027 | A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyNCT06642909 · Zuberitamab 600mg, Zuberitamab 1000mg, cyclosporine | BioRay Pharmaceutical Co., Ltd. | Kidney | Phase 2 | 135 | SealedSep 29, 2026 |
| Mar 31, 2027 | Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This MedicineNCT05846230 · BI 1291583, Placebo matching BI 1291583 | Boehringer Ingelheim | Respiratory | Phase 2 | 268 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Mar 31, 2027 | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.NCT05270044 · Encorafenib and Binimetinib, Placebo to match Encorafenib ; Placebo to match Binimetinib | Pierre Fabre Medicament | Oncology | Phase 3 | 815 | SealedSep 29, 2026 |
| Mar 31, 2027 | A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusNCT05648500 · Cenerimod, Placebo | Viatris Innovation GmbH | Immunology & inflammation | Phase 3 | 470 | SealedSep 29, 2026 |
| Mar 31, 2027 | Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsNCT07287189 · SAT-3247, Placebo | Satellos Bioscience, Inc. | Rare genetic disease | Phase 2 | 51 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Apr 2027 | Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)NCT06489028 · allo-APZ2-CVU, Placebo | RHEACELL GmbH & Co. KG | Other | Phase 3 | 250 | SealedSep 29, 2026 |
| Apr 2027 | A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsNCT07185776 · HRS-5632 Injection, HRS-5632 Injection Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Cardiovascular | Phase 2 | 203 | SealedSep 29, 2026 |
| Apr 2027 | Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133 · Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo | vTv Therapeutics | Diabetes & obesity | Phase 3 | 150 | SealedSep 29, 2026 |
| Apr 2027 | Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint InfectionNCT06621251 · TRL1068 (calpurbatug), a human monoclonal antibody, DAIR | Trellis Bioscience LLC | Infectious disease & vaccines | Phase 2 | 60 | SealedSep 29, 2026 |
| Apr 2027 | A Study With CIT-013 in HS PatientsNCT06993233 · CIT-013 high dose, CIT-013 medium dose, Placebo | Citryll BV | Immunology & inflammation | Phase 2 | 108 | SealedSep 29, 2026 |
| Apr 2027 | A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerNCT06279364 · SKB264, Paclitaxel, Nab-paclitaxel | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Oncology | Phase 3 | 537 | SealedSep 29, 2026 |
| Apr 2027 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerNCT05445778 · Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab | AbbVie | Oncology | Phase 3 | 520 | SealedSep 29, 2026 |
| Apr 2027 | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSNCT04057898 · MN-166, placebo | MediciNova | Neurology | Phase 2/3 | 234 | SealedSep 29, 2026 |
| Apr 2027 | Study of COYA 302 for the Treatment of ALSNCT07161999 · COYA 302, Placebo | Coya Therapeutics | Neurology | Phase 2/3 | 120 | SealedSep 29, 2026 |
| Apr 2027 | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisNCT06384976 · KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB | Kyverna Therapeutics | Neurology | Phase 2 | 120 | SealedSep 29, 2026 |
| Apr 1, 2027 | Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With MyopiaNCT07790640 · CTO0308, Vehicle (Placebo solution) | Taejoon Pharmaceutical Co., Ltd. | Ophthalmology | Phase 3 | 351 | SealedSep 29, 2026 |
| Apr 5, 2027 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantNCT03319667 · Isatuximab SAR650984, Bortezomib, Lenalidomide | Sanofi | Oncology | Phase 3 | 475 | SealedSep 29, 2026 |
| Apr 8, 2027 | A Study of CX11 Tablets in Patients With Type 2 Diabetes MellitusNCT07340320 · CX11, Placebo | Corxel Pharmaceuticals | Diabetes & obesity | Phase 2 | 251 | SealedSep 29, 2026 |
| Apr 8, 2027 | A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical RemissionNCT07156175 · SAR444336, Placebo | Sanofi | Immunology & inflammation | Phase 2 | 60 | SealedSep 29, 2026 |
| Apr 10, 2027 | A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaNCT05196035 · Finerenone (Kerendia, BAY94-8862), Placebo | Bayer | Kidney | Phase 3 | 219 | SealedSep 29, 2026 |
| Apr 12, 2027 | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)NCT05624749 · ianalumab, placebo | Novartis Pharmaceuticals | Immunology & inflammation | Phase 3 | 288 | SealedSep 29, 2026 |
| Apr 14, 2027 | A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)NCT06579755 · TDV, Placebo | Takeda | Infectious disease & vaccines | Phase 3 | 800 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Apr 15, 2027 | A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic DiseasesNCT06806592 · Nerandomilast, Placebo matching nerandomilast | Boehringer Ingelheim | Other | Phase 3 | 414 | SealedSep 29, 2026 |
| Apr 16, 2027 | A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)NCT07107945 · Empagliflozin, Placebo | Boehringer Ingelheim | Kidney | Phase 3 | 135 | SealedSep 29, 2026 |
| Apr 16, 2027 | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationNCT06106308 · Onvansertib, FOLFIRI, Bevacizumab | Cardiff Oncology | Oncology | Phase 2 | 110 | SealedSep 29, 2026 |
| Apr 18, 2027 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsNCT04432584 · Crovalimab, Eculizumab | Hoffmann-La Roche | Hematology | Phase 3 | 190 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Apr 19, 2027 | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)NCT06700343 · Ocrelizumab (US), Ocrelizumab (EU), ABP 692 | Amgen | Neurology | Phase 3 | 152 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Apr 22, 2027 | Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)NCT06497504 · Bepirovirsen, Placebo | GlaxoSmithKline | Infectious disease & vaccines | Phase 2 | 153 | SealedSep 29, 2026 |
| Apr 25, 2027 | A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisNCT06526182 · Lebrikizumab, Placebo | Almirall, S.A. | Immunology & inflammation | Phase 3 | 520 | SealedSep 29, 2026 |
| Apr 26, 2027 | A Study of DII235 in Adults With Elevated Lipoprotein(a)NCT07235046 · DII235, Saline | Novartis Pharmaceuticals | Other | Phase 2 | 234 | SealedSep 29, 2026 |
| Apr 26, 2027 | A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to AdultsNCT07794748 · PG4 Multivalent Vaccine, PG4 Multivalent Vaccine, PG4 Multivalent Vaccine | Pfizer | Infectious disease & vaccines | Phase 3 | 4,701 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Apr 27, 2027 | Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseaseNCT06987695 · Maridebart cafraglutide, Placebo | Amgen | Diabetes & obesity | Phase 3 | 279 | SealedSep 29, 2026 |
| Apr 28, 2027 | Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)NCT06111586 · Frexalimab, Placebo, Insulin | Sanofi | Diabetes & obesity | Phase 2 | 197 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Apr 29, 2027 | Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® MoleculeNCT06812988 · Brivekimig, Placebo | Sanofi | Diabetes & obesity | Phase 2 | 84 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Apr 30, 2027 | A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaNCT07064486 · BGM0504, BGM0504, Semaglutide | BrightGene Bio-Medical Technology Co., Ltd. | Diabetes & obesity | Phase 3 | 152 | SealedSep 29, 2026 |
| Apr 30, 2027 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLNCT03836261 · Acalabrutinib, Venetoclax, Chemoimmunotherapy | Acerta Pharma BV | Oncology | Phase 3 | 984 | SealedSep 29, 2026 |
| Apr 30, 2027 | Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot UlcersNCT06189638 · Antimicrobial Peptide PL-5 Topical Spray and Placebo | Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. | Diabetes & obesity | Phase 2 | 90 | SealedSep 29, 2026 |
| Apr 30, 2027 | Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)NCT07741526 · NPI-001, Placebo | Arctic Therapeutics | Neurology | Phase 2 | 33 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Apr 30, 2027 | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.NCT06517758 · Iptacopan, Matching Placebo | Novartis Pharmaceuticals | Immunology & inflammation | Phase 3 | 146 | SealedSep 29, 2026 |
| Apr 30, 2027 | Tigulixostat (IBI128) vs Febuxostat in GoutNCT07414394 · Febuxostat, Tigulixostat | Innovent Biologics Technology Limited (Shanghai R&D Center) | Immunology & inflammation | Phase 3 | 600 | SealedSep 29, 2026 |
| Apr 30, 2027 | A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic EsophagitisNCT06598462 · Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose | Uniquity One (UNI) | Other | Phase 2 | 184 | SealedSep 29, 2026 |
| May 2027 | Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's TypeNCT06052254 · 12 cm2 - 2 Active DMTS Patches, 6 cm2 - 1 Active and 1 Placebo DMTS Patches, Placebo - 2 Placebo DMTS Patches | Teikoku Pharma USA, Inc. | Neurology | Phase 2 | 150 | SealedSep 29, 2026 |
| May 2027 | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic DermatitisNCT06718101 · Lutikizumab, Placebo | AbbVie | Immunology & inflammation | Phase 2 | 83 | Not forecastNo arm registered as a control |
| May 2027 | A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06670196 · SKB264, Osimertinib | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Oncology | Phase 3 | 420 | SealedSep 29, 2026 |
| May 2027 | Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesNCT07458269 · Ribupatide, Placebo | Kailera | Diabetes & obesity | Phase 2 | 264 | SealedSep 29, 2026 |
| May 2027 | A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionNCT06672055 · VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3 | Vaxart | Infectious disease & vaccines | Phase 2 | 5,485 | SealedSep 29, 2026 |
| May 2027 | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.NCT06588686 · Buloxibutid, Placebo | Vicore Pharma AB | Respiratory | Phase 2 | 378 | SealedSep 29, 2026 |
| May 2027 | HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies StudyNCT07215468 · TMB-365, TMB-380, Baseline ART | TaiMed Biologics Inc. | Infectious disease & vaccines | Phase 2 | 88 | SealedSep 29, 2026 |
| May 2027 | PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerNCT06616532 · PM8002, Paclitaxel, Topotecan | Biotheus Inc. | Oncology | Phase 3 | 404 | SealedSep 29, 2026 |
| May 2027 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)NCT07076407 · Azetukalner, Placebo | Xenon Pharmaceuticals Inc. | Psychiatry | Phase 3 | 450 | SealedSep 29, 2026 |
| May 2027 | Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)NCT06843239 · Tibulizumab, Placebo | Zura Bio Inc | Immunology & inflammation | Phase 2 | 80 | SealedSep 29, 2026 |
| May 2027 | Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's DiseaseNCT06873334 · SKY-0515, SKY-0515 Placebo | Skyhawk Therapeutics, Inc. | Neurology | Phase 2/3 | 120 | SealedSep 29, 2026 |
| May 2027 | A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral AdrenoleukodystrophyNCT05819866 · Leriglitazone, Placebo | Minoryx Therapeutics, S.L. | Other | Phase 3 | 40 | SealedSep 29, 2026 |
| May 1, 2027 | Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDSNCT05938036 · ALT-100 mAb, ALT-100 (Placebo) | Aqualung Therapeutics Corp. | Other | Phase 2 | 15 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| May 1, 2027 | A Study of RSLV-132 in Females With Sjögren's DiseaseNCT06440525 · RSLV-132, Placebo | Resolve Therapeutics | Immunology & inflammation | Phase 2 | 106 | SealedSep 29, 2026 |
| May 2, 2027 | A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe EczemaNCT06807268 · Abrocitinib, Placebo | Pfizer | Immunology & inflammation | Phase 3 | 151 | SealedSep 29, 2026 |
| May 3, 2027 | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715 · Trastuzumab deruxtecan, Placebo, Taxane | AstraZeneca | Oncology | Phase 3 | 1,157 | SealedSep 29, 2026 |
| May 4, 2027 | Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaNCT05972551 · Romosozumab, Bisphosphonate | Amgen | Other | Phase 3 | 111 | SealedSep 29, 2026 |
| May 4, 2027 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)NCT04379596 · Fluorouracil (5-FU), Capecitabine, Durvalumab | AstraZeneca | Oncology | Phase 2 | 452 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| May 5, 2027 | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)NCT04380636 · Pembrolizumab, Olaparib, Placebo for olaparib | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 870 | SealedSep 29, 2026 |
| May 5, 2027 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)NCT06428396 · Belzutifan, Fulvestrant, Everolimus | Merck Sharp & Dohme LLC | Oncology | Phase 2 | 120 | SealedSep 29, 2026 |
| May 6, 2027 | A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)NCT05063162 · Rozanolixizumab, Placebo | UCB Biopharma SRL | Diabetes & obesity | Phase 3 | 113 | SealedSep 29, 2026 |
| May 6, 2027 | Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473 · Frexalimab, Teriflunomide, Placebo infusion | Sanofi | Neurology | Phase 3 | 1,655 | SealedSep 29, 2026 |
| May 10, 2027 | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)NCT06074588 · Sacituzumab tirumotecan, Docetaxel, Pemetrexed | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 556 | SealedSep 29, 2026 |
| May 10, 2027 | Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseNCT05030428 · Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Cardiovascular | Phase 3 | 17,004 | SealedSep 29, 2026 |
| May 11, 2027 | Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642 · Cagrilintide, Placebo | Novo Nordisk A/S | Diabetes & obesity | Phase 3 | 300 | SealedSep 29, 2026 |
| May 12, 2027 | Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 · Cagrilintide, Placebo (matched to Cagrilintide) | Novo Nordisk A/S | Diabetes & obesity | Phase 3 | 330 | SealedSep 29, 2026 |
| May 15, 2027 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian CancerNCT05605535 · Oregovomab, Paclitaxel, Carboplatin | CanariaBio Inc. | Oncology | Phase 2 | 88 | SealedSep 29, 2026 |
| May 17, 2027 | Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06736041 · PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine | Sanofi Pasteur, a Sanofi Company | Infectious disease & vaccines | Phase 3 | 1,714 | SealedSep 29, 2026 |
| May 17, 2027 | A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic DermatitisNCT07277660 · Galvokimig, Placebo | UCB Biopharma SRL | Immunology & inflammation | Phase 2 | 165 | SealedSep 29, 2026 |
| May 17, 2027 | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)NCT06799000 · Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 | Novartis Pharmaceuticals | Immunology & inflammation | Phase 3 | 588 | SealedSep 29, 2026 |
| May 17, 2027 | Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic DermatitisNCT07220577 · GIA632, Placebo | Novartis Pharmaceuticals | Immunology & inflammation | Phase 2 | 34 | SealedSep 29, 2026 |
| May 18, 2027 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesNCT06671483 · Zasocitinib, Active Comparator, Placebo | Takeda | Immunology & inflammation | Phase 3 | 1,583 | SealedSep 29, 2026 |
| May 18, 2027 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesNCT06671496 · Zasocitinib, Placebo | Takeda | Immunology & inflammation | Phase 3 | 601 | Not forecastNo arm registered as a control |
| May 19, 2027 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)NCT05624554 · Nemtabrutinib, Fludarabine, Cyclophosphamide | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 300 | SealedSep 29, 2026 |
| May 20, 2027 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisNCT03958877 · BIIB017 (peginterferon beta-1a), Interferon beta type 1a | Biogen | Neurology | Phase 3 | 152 | SealedSep 29, 2026 |
| May 27, 2027 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)NCT05173987 · pembrolizumab, carboplatin, paclitaxel | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 280 | SealedSep 29, 2026 |
| May 27, 2027 | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)NCT05973773 · TAS6417 | Taiho Oncology, Inc. | Oncology | Phase 3 | 285 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| May 29, 2027 | A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)NCT07230119 · Zovaglutide dose 1, Zovaglutide dose 2, Placebo | Beijing QL Biopharmaceutical Co.,Ltd | Diabetes & obesity | Phase 3 | 755 | SealedSep 29, 2026 |
| May 31, 2027 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)NCT05881408 · delandistrogene moxeparvovec, placebo | Sarepta Therapeutics, Inc. | Rare genetic disease | Phase 3 | 148 | SealedSep 29, 2026 |
| May 31, 2027 | A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)NCT06537414 · Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen | GlaxoSmithKline | Infectious disease & vaccines | Phase 2 | 283 | Not forecastNo arm registered as a control |
| May 31, 2027 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656 · CT1812, Placebo | Cognition Therapeutics | Neurology | Phase 2 | 540 | SealedSep 29, 2026 |
| May 31, 2027 | Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140 · Amivantamab IV, Amivantamab SC, Lazertinib | Janssen Research & Development, LLC | Oncology | Phase 2 | 305 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 2027 | Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)NCT07146022 · VDPHL01 QD, Placebo, VDPHL01 BID | Veradermics, Inc. | Immunology & inflammation | Phase 3 | 552 | SealedSep 29, 2026 |
| Jun 2027 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)NCT06857175 · BL-B01D1, Docetaxel or Paclitaxel | Sichuan Baili Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 515 | SealedSep 29, 2026 |
| Jun 2027 | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With ChemotherapyNCT06449209 · BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide | BioNTech SE | Oncology | Phase 2 | 110 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 2027 | A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With EndometriosisNCT07260669 · Vipoglanstat, Placebo | Gesynta Pharma AB | Other | Phase 2 | 213 | SealedSep 29, 2026 |
| Jun 2027 | A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late XerostomiaNCT05926765 · AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, Placebo | MeiraGTx, LLC | Oncology | Phase 2 | 290 | SealedSep 29, 2026 |
| Jun 2027 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSENCT04919226 · 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution | ITM Solucin GmbH | Oncology | Phase 3 | 259 | SealedSep 29, 2026 |
| Jun 2027 | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)NCT05566795 · Tovorafenib, Chemotherapeutic Agent | Day One Biopharmaceuticals, Inc. | Oncology | Phase 3 | 418 | SealedSep 29, 2026 |
| Jun 2027 | AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial DysfunctionNCT07368959 · Combination Product: AURN001 + Y-27632, Placebo | Aurion Biotech | Ophthalmology | Phase 3 | 130 | SealedSep 29, 2026 |
| Jun 2027 | A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerNCT03980054 · Pyrotinib, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Oncology | Phase 3 | 2,135 | SealedSep 29, 2026 |
| Jun 2027 | A Study of SHR-1819 in Patients With Moderate-to-severe Atopic DermatitisNCT07321951 · SHR-1819 Injection, SHR-1819 Injection Blank Preparation | Guangdong Hengrui Pharmaceutical Co., Ltd | Immunology & inflammation | Phase 2 | 201 | Not forecastNo arm registered as a control |
| Jun 2027 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)NCT05578976 · Epcoritamab, Cyclophosphamide, Rituximab | Genmab | Oncology | Phase 3 | 900 | Not forecastNo arm registered as a control |
| Jun 2027 | Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute PancreatitisNCT07308392 · HRS-7249 injection set, SHR-1918 injection set, HRS-7249 injection placebo set | Fujian Shengdi Pharmaceutical Co., Ltd. | Diabetes & obesity | Phase 2 | 119 | SealedSep 29, 2026 |
| Jun 2027 | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)NCT06726265 · eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed | Immutep S.A.S. | Oncology | Phase 3 | 756 | SealedSep 29, 2026 |
| Jun 2027 | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084 · Acellular Tissue Engineered Vessel (ATEV), AVF | Humacyte, Inc. | Kidney | Phase 3 | 121 | SealedSep 29, 2026 |
| Jun 2027 | Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCNCT03257033 · Gemcitabine, nab-paclitaxel, RenovoCath | RenovoRx | Oncology | Phase 3 | 190 | SealedSep 29, 2026 |
| Jun 2027 | A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 · AP01, Placebo | Avalyn Pharma Inc. | Immunology & inflammation | Phase 2 | 398 | SealedSep 29, 2026 |
| Jun 2027 | A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 · Retatrutide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 250 | SealedSep 29, 2026 |
| Jun 2027 | A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisNCT07217015 · KT-621, Placebo | Kymera Therapeutics, Inc. | Immunology & inflammation | Phase 2 | 200 | SealedSep 29, 2026 |
| Jun 2027 | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT06864988 · 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) | 4D Molecular Therapeutics | Ophthalmology | Phase 3 | 480 | SealedSep 29, 2026 |
| Jun 3, 2027 | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaNCT06840392 · Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 | Novartis Pharmaceuticals | Immunology & inflammation | Phase 3 | 565 | SealedSep 29, 2026 |
| Jun 14, 2027 | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityNCT07639021 · NNC0662-0419, Semaglutide, NNC0662-0419 Placebo | Novo Nordisk A/S | Diabetes & obesity | Phase 2 | 233 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 21, 2027 | Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319 · Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo | Sanofi | Respiratory | Phase 2 | 556 | SealedSep 29, 2026 |
| Jun 23, 2027 | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisNCT03731260 · Avapritinib, Placebo | Blueprint Medicines Corporation | Other | Phase 2 | 251 | SealedSep 29, 2026 |
| Jun 25, 2027 | Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.NCT06473779 · Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®) | AstraZeneca | Respiratory | Phase 3 | 310 | Not forecastNo arm registered as a control |
| Jun 26, 2027 | A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or OverweightNCT07662122 · BI 3034701, Placebo matching BI 3034701 | Boehringer Ingelheim | Diabetes & obesity | Phase 2 | 345 | SealedSep 29, 2026 |
| Jun 28, 2027 | A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic ArthritisNCT07321873 · JNJ-88545223, Placebo | Janssen Research & Development, LLC | Immunology & inflammation | Phase 2 | 157 | SealedSep 29, 2026 |
| Jun 30, 2027 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCNCT04550260 · Durvalumab, Placebo, cisplatin + fluorouracil | AstraZeneca | Oncology | Phase 3 | 640 | SealedSep 29, 2026 |
| Jun 30, 2027 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)NCT03178552 · Alectinib, Atezolizumab, Pemetrexed | Hoffmann-La Roche | Oncology | Phase 2/3 | 1,000 | SealedSep 29, 2026 |
| Jun 30, 2027 | A Phase 2 Study of YA-101 in Patients With Multiple System AtrophyNCT06848231 · YA-101, Placebo | Dasher Neuroscience Inc. | Other | Phase 2 | 75 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jun 30, 2027 | A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)NCT05562947 · PDS With Ranibizumab (100 mg/mL), Ranibizumab (10 mg/mL) | Hoffmann-La Roche | Ophthalmology | Phase 3 | 68 | Not forecastNo arm registered as a control |
| Jun 30, 2027 | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaNCT03967977 · Tislelizumab, Placebo, Cisplatin | BeiGene | Oncology | Phase 3 | 420 | SealedSep 29, 2026 |
| Jun 30, 2027 | A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBMNCT03862430 · NanO2TM, Placebo Saline Infusion | NuvOx LLC | Oncology | Phase 2 | 87 | SealedSep 29, 2026 |
| Jun 30, 2027 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic AtrophyNCT05949593 · Tinlarebant, Placebo | Belite Bio, Inc | Other | Phase 3 | 429 | SealedSep 29, 2026 |
| Jun 30, 2027 | Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical TrialNCT04003857 · PNEUMOSTEM®, normal saline | Medipost Co Ltd. | Respiratory | Phase 2 | 60 | SealedSep 29, 2026 |
| Jun 30, 2027 | A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerNCT06792695 · Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab | AstraZeneca | Oncology | Phase 2 | 82 | SealedSep 29, 2026 |
| Jul 2027 | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic SyndromeNCT04401748 · Venetoclax, Azacitidine, Placebo | AbbVie | Oncology | Phase 3 | 531 | SealedSep 29, 2026 |
| Jul 2027 | A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.NCT06917404 · Pentosan Polysulfate Sodium twice weekly, Placebo | Paradigm Biopharmaceuticals Ltd. | Immunology & inflammation | Phase 3 | 466 | SealedSep 29, 2026 |
| Jul 2027 | A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01NCT06770933 · VX-01, Placebo | Vantage Biosciences Ltd | Ophthalmology | Phase 2 | 100 | SealedSep 29, 2026 |
| Jul 2027 | Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe PainNCT04333576 · Elagolix, Placebo, Combined Oral Contraceptive | AbbVie | Pain | Phase 3 | 800 | SealedSep 29, 2026 |
| Jul 2027 | Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back PainNCT06325566 · Rexlemestrocel-L + HA mixture, Saline | Mesoblast, Ltd. | Pain | Phase 3 | 300 | SealedSep 29, 2026 |
| Jul 2027 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromeNCT06684847 · Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Immunology & inflammation | Phase 3 | 631 | SealedSep 29, 2026 |
| Jul 2027 | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCNCT06419621 · PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Oncology | Phase 3 | 392 | SealedSep 29, 2026 |
| Jul 2027 | A Phase 3 Study of NTLA-2001 in ATTRv-PNNCT06672237 · nexiguran ziclumeran, Normal Saline as Placebo | Intellia Therapeutics | Neurology | Phase 3 | 67 | SealedSep 29, 2026 |
| Jul 1, 2027 | RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck CancerNCT05966194 · RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2 | EpicentRx, Inc. | Oncology | Phase 2 | 216 | SealedSep 29, 2026 |
| Jul 1, 2027 | VK2735 for Weight Management Phase 3NCT07104500 · VK2735 | Viking Therapeutics, Inc. | Other | Phase 3 | 4,500 | SealedSep 29, 2026 |
| Jul 1, 2027 | VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 · VK2735 | Viking Therapeutics, Inc. | Diabetes & obesity | Phase 3 | 1,100 | SealedSep 29, 2026 |
| Jul 7, 2027 | Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityNCT07497880 · KAI-7535, Placebo | Kailera | Diabetes & obesity | Phase 2 | 306 | SealedSep 29, 2026 |
| Jul 14, 2027 | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)NCT06079879 · Bomedemstat, Anagrelide, Busulfan | Merck Sharp & Dohme LLC | Cardiovascular | Phase 3 | 340 | SealedSep 29, 2026 |
| Jul 15, 2027 | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT05057494 · Acalabrutinib, Venetoclax, Obinutuzumab | AstraZeneca | Oncology | Phase 3 | 607 | Not forecastNo arm registered as a control |
| Jul 15, 2027 | A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung CancerNCT07881705 · Trilaciclib, Trilaciclib Placebo, Etoposide Injection | Jiangsu Simcere Pharmaceutical Co., Ltd. | Oncology | Phase 3 | 106 | SealedOct 20, 2026 |
| Jul 16, 2027 | A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaNCT05664737 · Luspatercept, Placebo | Bristol-Myers Squibb | Hematology | Phase 2 | 189 | SealedSep 29, 2026 |
| Jul 16, 2027 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07047118 · JSB462, AAA617 | Novartis Pharmaceuticals | Oncology | Phase 2 | 138 | SealedSep 29, 2026 |
| Jul 20, 2027 | A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DMENCT04108156 · PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange | Hoffmann-La Roche | Ophthalmology | Phase 3 | 672 | SealedSep 29, 2026 |
| Jul 22, 2027 | A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)NCT07044297 · MK-8527, FTC/TDF, Placebo to MK-8527 | Merck Sharp & Dohme LLC | Infectious disease & vaccines | Phase 3 | 4,390 | SealedSep 29, 2026 |
| Jul 27, 2027 | Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.NCT07007793 · Baxdrostat, Placebo | AstraZeneca | Other | Phase 3 | 212 | SealedSep 29, 2026 |
| Jul 30, 2027 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentNCT05455320 · Talquetamab, Daratumumab, Pomalidomide | Janssen Research & Development, LLC | Oncology | Phase 3 | 864 | Not forecastNo arm registered as a control |
| Jul 30, 2027 | A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2NCT06072183 · Ritlecitinib, Ritlecitinib, Placebo | Pfizer | Immunology & inflammation | Phase 3 | 1,571 | SealedSep 29, 2026 |
| Jul 30, 2027 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)NCT06635824 · Acasunlimab, Pembrolizumab, Docetaxel | Genmab | Oncology | Phase 3 | 191 | SealedSep 29, 2026 |
| Jul 30, 2027 | Volrustomig Priming Regimens Exploratory Phase II Platform StudyNCT06448754 · Volrustomig, Carboplatin, Pemetrexed | AstraZeneca | Oncology | Phase 2 | 194 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Jul 30, 2027 | A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisNCT06470048 · Placebo, Ianalumab | Novartis Pharmaceuticals | Immunology & inflammation | Phase 2 | 203 | SealedSep 29, 2026 |
| Jul 30, 2027 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesNCT06465914 · 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo | Shanghai Bovax Biotechnology Co., Ltd. | Oncology | Phase 3 | 9,000 | SealedSep 29, 2026 |
| Jul 30, 2027 | Clinical Application of Stem Cell Educator Therapy in Alopecia AreataNCT04011748 · Stem Cell Educator therapy | Throne Biotechnologies Inc. | Immunology & inflammation | Phase 2 | 20 | Not forecastNo arm registered as a control |
| Jul 30, 2027 | A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesNCT05794906 · Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT | Bayer | Oncology | Phase 3 | 985 | SealedSep 29, 2026 |
| Jul 31, 2027 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)NCT06510816 · Vonaprument, Sham Administration | Annexon, Inc. | Ophthalmology | Phase 3 | 659 | SealedSep 29, 2026 |
| Aug 2027 | A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)NCT06464991 · Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomide | Nanjing IASO Biotechnology Co., Ltd. | Oncology | Phase 3 | 260 | SealedSep 29, 2026 |
| Aug 2027 | Long-Term PEA Safety StudyNCT06717867 · Palmitoylethanolamide (PEA), Placebo | RDC Clinical Pty Ltd | Other | Phase 2 | 200 | Not forecastNot a treatment or prevention trial |
| Aug 2027 | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisNCT07265479 · Tapinarof cream, 1%, Vehicle Cream | Organon and Co | Immunology & inflammation | Phase 3 | 187 | SealedSep 29, 2026 |
| Aug 2027 | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabNCT06880744 · Risankizumab, Risankizumab, Vedolizumab | AbbVie | Immunology & inflammation | Phase 3 | 573 | SealedSep 29, 2026 |
| Aug 2027 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472 · Orforglipron, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 600 | SealedSep 29, 2026 |
| Aug 2027 | ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)NCT06373731 · Elamipretide, Placebo | Stealth BioTherapeutics Inc. | Ophthalmology | Phase 3 | 313 | SealedSep 29, 2026 |
| Aug 2027 | A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal CancerNCT06614192 · Telisotuzumab Adizutecan | AbbVie | Oncology | Phase 2 | 74 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Aug 2027 | REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman SyndromeNCT06914609 · obudanersen, Placebo | Ionis Pharmaceuticals, Inc. | Other | Phase 3 | 156 | SealedSep 29, 2026 |
| Aug 2027 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459 · Orforglipron, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 800 | SealedSep 29, 2026 |
| Aug 2027 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenNCT07087054 · Paltusotine, Placebo | Crinetics Pharmaceuticals Inc. | Oncology | Phase 3 | 141 | SealedSep 29, 2026 |
| Aug 2027 | A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODNCT05933200 · Triheptanoin, MCT Oil | Ultragenyx Pharmaceutical Inc | Other | Phase 3 | 69 | SealedSep 29, 2026 |
| Aug 2027 | WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06967805 · MTX-463, Placebo | Mediar Therapeutics | Respiratory | Phase 2 | 168 | SealedSep 29, 2026 |
| Aug 2027 | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792 · Orforglipron, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 1,400 | Not forecastNot a treatment or prevention trial |
| Aug 1, 2027 | A Study Evaluating BFB759 in Moderate to Severe Hidradenitis SuppurativaNCT07287644 · BFB759, Placebo for BFB759 | Bluefin Biomedicine, Inc. | Immunology & inflammation | Phase 2/3 | 210 | SealedSep 29, 2026 |
| Aug 2, 2027 | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionNCT05120349 · Osimertinib, Placebo | AstraZeneca | Oncology | Phase 3 | 390 | SealedSep 29, 2026 |
| Aug 4, 2027 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantNCT05317416 · Elranatamab, Lenalidomide, Lenalidomide | Pfizer | Oncology | Phase 3 | 854 | SealedSep 29, 2026 |
| Aug 4, 2027 | A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932 · PF-08653945, PF-08653944, Placebo | Pfizer | Diabetes & obesity | Phase 2 | 940 | Not forecastNo arm registered as a control |
| Aug 6, 2027 | A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee OsteoarthritisNCT04368806 · JointStem, Placebo Control | Nature Cell Co. Ltd. | Immunology & inflammation | Phase 2/3 | 173 | SealedSep 29, 2026 |
| Aug 7, 2027 | Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS SymptomsNCT04856982 · Tofersen, Placebo | Biogen | Neurology | Phase 3 | 158 | SealedSep 29, 2026 |
| Aug 9, 2027 | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyNCT06393712 · Placebo, ALN-APP | Alnylam Pharmaceuticals | Rare genetic disease | Phase 2 | 210 | SealedSep 29, 2026 |
| Aug 9, 2027 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaNCT06356129 · Golcadomide, Placebo, Rituximab | Celgene | Oncology | Phase 3 | 850 | SealedSep 29, 2026 |
| Aug 10, 2027 | A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)NCT06891066 · ISL, ULO, BIC/FTC/TAF | Merck Sharp & Dohme LLC | Infectious disease & vaccines | Phase 2 | 150 | SealedSep 29, 2026 |
| Aug 10, 2027 | A Study of Zigakibart in Adults With IgA NephropathyNCT05852938 · BION-1301, Placebo | Novartis Pharmaceuticals | Kidney | Phase 3 | 383 | SealedSep 29, 2026 |
| Aug 20, 2027 | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)NCT07037771 · zodasiran Injection, Placebo | Arrowhead Pharmaceuticals | Cardiovascular | Phase 3 | 70 | SealedSep 29, 2026 |
| Aug 20, 2027 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686 · Maridebart cafraglutide, Placebo | Amgen | Diabetes & obesity | Phase 3 | 250 | SealedSep 29, 2026 |
| Aug 23, 2027 | A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older AdultsNCT05371080 · HZ/su vaccine | GlaxoSmithKline | Infectious disease & vaccines | Phase 3 | 3,038 | Not forecastNo arm registered as a control |
| Aug 25, 2027 | A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252 · Maridebart cafraglutide, Placebo | Amgen | Diabetes & obesity | Phase 2 | 180 | SealedSep 29, 2026 |
| Aug 25, 2027 | Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06975878 · PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine | Sanofi | Infectious disease & vaccines | Phase 3 | 1,092 | SealedSep 29, 2026 |
| Aug 30, 2027 | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765 · Maridebart cafraglutide, Placebo | Amgen | Other | Phase 3 | 250 | SealedSep 29, 2026 |
| Aug 30, 2027 | Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic UlcerNCT06284876 · Ilaprazole, Lansoprazole, Ilaprazole Placebo | Il-Yang Pharm. Co., Ltd. | Other | Phase 3 | 416 | SealedSep 29, 2026 |
| Aug 31, 2027 | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943 · CTX-009, Paclitaxel | Compass Therapeutics | Oncology | Phase 2/3 | 168 | SealedSep 29, 2026 |
| Aug 31, 2027 | MHB018A Treatment in Patients With Chronic Thyroid Eye DiseaseNCT07257185 · MHB018A injection, MHB018A injection Placebo | Minghui Pharmaceutical (Hangzhou) Ltd | Ophthalmology | Phase 3 | 150 | SealedSep 29, 2026 |
| Aug 31, 2027 | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsNCT05671510 · Gotistobart, Docetaxel | OncoC4, Inc. | Oncology | Phase 3 | 630 | SealedSep 29, 2026 |
| Sep 2027 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult ParticipantsNCT06345339 · Armour Thyroid, Levothyroxine | AbbVie | Endocrine & bone | Phase 2/3 | 2,701 | Not forecastNo arm registered as a control |
| Sep 2027 | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · Orforglipron, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 487 | SealedSep 29, 2026 |
| Sep 2027 | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)NCT06966479 · Verekitug, Placebo | Upstream Bio Inc. | Respiratory | Phase 2 | 396 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 2027 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.NCT06732895 · Navepegritide, Placebo for navepegritide | Ascendis Pharma A/S | Other | Phase 2 | 25 | SealedSep 29, 2026 |
| Sep 2027 | A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic AsthmaNCT06653322 · HR-1703, Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | Respiratory | Phase 3 | 401 | SealedSep 29, 2026 |
| Sep 2027 | A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative ColitisNCT06257875 · Lutikizumab, Lutikizumab, Adalimumab | AbbVie | Immunology & inflammation | Phase 2 | 156 | Not forecastNo arm registered as a control |
| Sep 2027 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 · Retatrutide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 586 | SealedSep 29, 2026 |
| Sep 2027 | Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)NCT05775848 · BBP-418 (ribitol), Placebo | ML Bio Solutions, Inc. | Other | Phase 3 | 112 | SealedSep 29, 2026 |
| Sep 2027 | A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisNCT06754462 · IMVT-1402, Placebo | Immunovant Sciences GmbH | Immunology & inflammation | Phase 2 | 120 | SealedSep 29, 2026 |
| Sep 2027 | Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) DeficiencyNCT05345171 · DTX301, Placebo, Oral Corticosteroids | Ultragenyx Pharmaceutical Inc | Other | Phase 3 | 37 | Not forecastNo arm registered as a control |
| Sep 2027 | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433NCT03345823 · Upadacitinib, Placebo for Upadacitinib | AbbVie | Immunology & inflammation | Phase 3 | 747 | Not forecastNo arm registered as a control |
| Sep 2027 | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · Orforglipron, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 487 | SealedSep 29, 2026 |
| Sep 2027 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044 · Botensilimab, Balstilimab, Standard of Care | Agenus Inc. | Oncology | Phase 2 | 234 | SealedSep 29, 2026 |
| Sep 2027 | A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · Orforglipron, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 974 | Not forecastNot a treatment or prevention trial |
| Sep 2027 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaNCT06679985 · Casdozokitug, Toripalimab, Bevacizumab | Coherus Oncology, Inc. | Oncology | Phase 2 | 72 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 1, 2027 | REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 · Cagrilintide, Semaglutide, Placebo | Novo Nordisk A/S | Cardiovascular | Phase 3 | 7,101 | SealedSep 29, 2026 |
| Sep 1, 2027 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · Dato-DXd, Durvalumab, Capecitabine | AstraZeneca | Oncology | Phase 3 | 1,174 | SealedSep 29, 2026 |
| Sep 10, 2027 | Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06824181 · PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine | Sanofi | Infectious disease & vaccines | Phase 3 | 580 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 12, 2027 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485 · BMS-986365, Enzalutamide, Abiraterone | Celgene | Oncology | Phase 3 | 960 | SealedSep 29, 2026 |
| Sep 15, 2027 | A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System AtrophyNCT06568237 · TEV-56286, Placebo | Teva Branded Pharmaceutical Products R&D LLC | Other | Phase 2 | 349 | SealedSep 29, 2026 |
| Sep 21, 2027 | Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisNCT05126277 · ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c. | Novartis Pharmaceuticals | Kidney | Phase 3 | 452 | SealedSep 29, 2026 |
| Sep 21, 2027 | Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850 · MET097, Placebo | Pfizer | Diabetes & obesity | Phase 3 | 3,578 | SealedSep 29, 2026 |
| Sep 24, 2027 | Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative ColitisNCT03221036 · Vedolizumab IV, Placebo | Takeda | Immunology & inflammation | Phase 3 | 392 | SealedSep 29, 2026 |
| Sep 28, 2027 | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05785767 · fianlimab, cemiplimab, Placebo | Regeneron Pharmaceuticals | Oncology | Phase 2/3 | 149 | Not forecastNo arm registered as a control |
| Sep 28, 2027 | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)NCT06456346 · Bomedemstat, Hydroxyurea, Bomedemstat placebo | Merck Sharp & Dohme LLC | Cardiovascular | Phase 3 | 300 | SealedSep 29, 2026 |
| Sep 29, 2027 | UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)NCT07648225 · UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg, UBT251 Injection Placebo 4.0 mg | The United Bio-Technology (Hengqin) Co., Ltd. | Diabetes & obesity | Phase 3 | 600 | SealedSep 29, 2026 |
| Sep 30, 2027 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · Saruparib, Placebo, Abiraterone Acetate | AstraZeneca | Oncology | Phase 3 | 1,898 | SealedSep 29, 2026 |
| Sep 30, 2027 | ONO-4059 Study in Patients With Steroid-resistant PemphigusNCT06696716 · ONO-4059, ONO-4059 placebo | Ono Pharmaceutical Co., Ltd. | Immunology & inflammation | Phase 3 | 34 | SealedSep 29, 2026 |
| Sep 30, 2027 | THIO Sequenced With Cemiplimab in Advanced NSCLCNCT05208944 · 6-Thio-2'-Deoxyguanosine, Cemiplimab | Maia Biotechnology | Oncology | Phase 2 | 227 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Sep 30, 2027 | RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860 · Pemvidutide, Placebo | Altimmune, Inc. | Other | Phase 2 | 121 | SealedSep 29, 2026 |
| Sep 30, 2027 | Evaluating Efficacy and Safety of CBD TPM Capsules for Use in InsomniaNCT05840822 · Cannabidiol (CBD) Capsule 75mg, Placebo | Avecho Biotechnology | Psychiatry | Phase 3 | 519 | SealedSep 29, 2026 |
| Sep 30, 2027 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorNCT06241118 · Amlitelimab, Placebo, Topical corticosteroids | Sanofi | Immunology & inflammation | Phase 3 | 464 | SealedSep 29, 2026 |
| Sep 30, 2027 | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT06138613 · Tradipitant | Vanda Pharmaceuticals | Other | Phase 3 | 705 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 2027 | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDNCT06981078 · Verekitug, Placebo | Upstream Bio Inc. | Respiratory | Phase 2 | 666 | SealedSep 29, 2026 |
| Oct 2027 | A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick ExposureNCT07562087 · TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo | Tarsus Pharmaceuticals, Inc. | Other | Phase 2 | 722 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 2027 | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07474792 · ORKA-002, Placebo | Oruka Therapeutics, Inc. | Immunology & inflammation | Phase 2 | 160 | SealedSep 29, 2026 |
| Oct 2027 | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereNCT06900543 · NRT6003 Injection, cTACE | Chengdu New Radiomedicine Technology Co. LTD. | Oncology | Phase 3 | 108 | SealedSep 29, 2026 |
| Oct 2027 | CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMENCT07449923 · EYP-1901, Aflibercept (2.0 mg) | EyePoint Pharmaceuticals, Inc. | Ophthalmology | Phase 3 | 240 | SealedSep 29, 2026 |
| Oct 2027 | A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous NephropathyNCT05707377 · Zanubrutinib, Tacrolimus | BeOne Medicines | Kidney | Phase 2/3 | 178 | SealedSep 29, 2026 |
| Oct 2027 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · Imlunestrant, Tamoxifen, Anastrozole | Eli Lilly and Company | Oncology | Phase 3 | 8,000 | SealedSep 29, 2026 |
| Oct 2027 | COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMENCT07449936 · EYP-1901, Aflibercept (2.0 mg) | EyePoint Pharmaceuticals, Inc. | Ophthalmology | Phase 3 | 240 | SealedSep 29, 2026 |
| Oct 2027 | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight LossNCT07446998 · Enobosarm, Semaglutide (Wegovy) weekly injection | Veru Inc. | Diabetes & obesity | Phase 2 | 239 | SealedSep 29, 2026 |
| Oct 2027 | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · Tirzepatide, Placebo | Eli Lilly and Company | Diabetes & obesity | Phase 3 | 15,374 | SealedSep 29, 2026 |
| Oct 1, 2027 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaNCT06047080 · Glofitamab, Polatuzumab vedotin, Rituximab | Hoffmann-La Roche | Oncology | Phase 3 | 1,130 | SealedSep 29, 2026 |
| Oct 4, 2027 | Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney DiseaseNCT06824987 · AZD2373-Arm 1, AZD2373-Arm 2, Placebo | AstraZeneca | Kidney | Phase 2 | 63 | SealedSep 29, 2026 |
| Oct 11, 2027 | Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney TransplantationNCT06744647 · ALXN2030, Placebo | Alexion Pharmaceuticals, Inc. | Kidney | Phase 2 | 47 | SealedSep 29, 2026 |
| Oct 11, 2027 | Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisNCT07160608 · Placebo, Tarperprumig | Alexion Pharmaceuticals, Inc. | Immunology & inflammation | Phase 2 | 78 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 12, 2027 | A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653 · PF-08653944, Placebo | Pfizer | Diabetes & obesity | Phase 3 | 1,078 | SealedSep 29, 2026 |
| Oct 18, 2027 | This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FCNCT07723924 · plecanatide, Placebo | Bausch Health Americas, Inc. | Other | Phase 2 | 180 | SealedSep 29, 2026 |
| Oct 22, 2027 | Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06824194 · PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine | Sanofi | Infectious disease & vaccines | Phase 3 | 2,360 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Oct 28, 2027 | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)NCT04624204 · Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline) | Merck Sharp & Dohme LLC | Oncology | Phase 3 | 672 | SealedSep 29, 2026 |
| Oct 29, 2027 | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialNCT05334368 · Depemokimab, Placebo | GlaxoSmithKline | Other | Phase 3 | 110 | SealedSep 29, 2026 |
| Oct 31, 2027 | A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)NCT04573023 · JR-141, Idursulfase, JR-141 or Idursulfase | JCR Pharmaceuticals Co., Ltd. | Rare genetic disease | Phase 3 | 86 | Not forecastNo arm registered as a control |
| Oct 31, 2027 | A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in AdultsNCT06625060 · Corabotase, Placebo, Corabotase dose A | Ipsen | Neurology | Phase 2 | 670 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 2027 | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)NCT04662255 · Pirtobrutinib, Ibrutinib, Acalabrutinib | Loxo Oncology, Inc. | Oncology | Phase 3 | 500 | SealedSep 29, 2026 |
| Nov 2027 | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineNCT06417775 · Ubrogepant, Placebo for Ubrogepant | AbbVie | Neurology | Phase 3 | 496 | Not forecastNo arm registered as a control |
| Nov 2027 | A Clinical Study of KLH-2109 in Patients With EndometriosisNCT07015268 · KLH-2109, Leuprorelin acetate | Kissei Pharmaceutical Co., Ltd. | Other | Phase 3 | 288 | SealedSep 29, 2026 |
| Nov 2027 | A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)NCT05026866 · Donanemab, Placebo | Eli Lilly and Company | Neurology | Phase 3 | 2,996 | SealedSep 29, 2026 |
| Nov 2027 | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaqueNCT06305559 · obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Placebo | NewAmsterdam Pharma | Cardiovascular | Phase 3 | 300 | SealedSep 29, 2026 |
| Nov 2027 | Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsNCT07147400 · 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation, RABIVAX-S | Serum Institute of India Pvt. Ltd. | Infectious disease & vaccines | Phase 2 | 1,200 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 2027 | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)NCT06503731 · Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe | argenx | Kidney | Phase 2 | 33 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 1, 2027 | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsNCT05687266 · Datopotamab deruxtecan, Durvalumab, Carboplatin | AstraZeneca | Oncology | Phase 3 | 1,350 | SealedSep 29, 2026 |
| Nov 1, 2027 | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)NCT04862663 · Capivasertib, Fulvestrant, Palbociclib | AstraZeneca | Oncology | Phase 3 | 893 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |
| Nov 7, 2027 | A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesNCT03811561 · Semaglutide, Placebo (semaglutide) | Novo Nordisk A/S | Diabetes & obesity | Phase 3 | 1,500 | SealedSep 29, 2026 |
| Nov 8, 2027 | A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.NCT05064878 · Fenfluramine, Placebo | Zogenix, Inc. | Neurology | Phase 3 | 87 | SealedSep 29, 2026 |
| Nov 10, 2027 | A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)NCT06534983 · Autogene Cevumeran, Nivolumab | Hoffmann-La Roche | Oncology | Phase 2 | 62 | Not forecastIts main goal is safety, dosing or drug levels, not benefit |